# DNA mismatch repair gene variant classification: evaluating the utility of somatic mutations and mismatch repair deficient colonic

### 3 crypts and endometrial glands

- 4 Romy Walker<sup>1,2\*</sup>, Khalid Mahmood<sup>1,2,3</sup>, Julia Como<sup>1,2</sup>, Mark Clendenning<sup>1,2</sup>, Jihoon E. Joo<sup>1,2</sup>,
- 5 Peter Georgeson<sup>1,2</sup>, Sharelle Joseland<sup>1,2</sup>, Susan G. Preston<sup>1,2</sup>, Bernard J. Pope<sup>1,2,3</sup>, James M.
- 6 Chan<sup>1,2</sup>, Rachel Austin<sup>4</sup>, Jasmina Bojadzieva<sup>5</sup>, Ainsley Campbell<sup>5</sup>, Emma Edwards<sup>6</sup>, Margaret
- 7 Gleeson<sup>7</sup>, Annabel Goodwin<sup>8,9</sup>, Marion T. Harris<sup>10</sup>, Emilia Ip<sup>11</sup>, Judy Kirk<sup>7</sup>, Julia Mansour<sup>12</sup>,
- 8 Helen Marfan<sup>4</sup>, Cassandra Nichols<sup>13</sup>, Nicholas Pachter<sup>13,14,15</sup>, Abiramy Ragunathan<sup>7</sup>, Allan
- 9 Spigelman<sup>8,16,17</sup>, Rachel Susman<sup>4</sup>, Michael Christie<sup>18,19</sup>, Mark A. Jenkins<sup>2,20</sup>, Rish K. Pai<sup>21</sup>,
- 10 Christophe Rosty<sup>1,2,22,23</sup>, Finlay A. Macrae<sup>24,25,26</sup>, Ingrid M. Winship<sup>24,26†,</sup> Daniel D. Buchanan
- 11  $1^{1,2,24\dagger}$  for the ANGELS study
- 12
- <sup>1</sup>*Colorectal Oncogenomics Group, Department of Clinical Pathology, Victorian Comprehensive*
- 14 Cancer Centre, The University of Melbourne, Melbourne, VIC, Australia
- <sup>15</sup> <sup>2</sup>University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre,
- 16 Melbourne, VIC, Australia
- <sup>3</sup>Melbourne Bioinformatics, The University of Melbourne, Melbourne, VIC, Australia
- <sup>4</sup>Genetic Health Queensland, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
- 19 <sup>5</sup>Clinical Genetics Unit, Austin Health, Melbourne, VIC, Australia
- 20 <sup>6</sup>Familial Cancer Service, Westmead Hospital, Sydney, NSW, Australia
- 21 <sup>7</sup>*Hunter Family Cancer Service, Newcastle, NSW, Australia*
- 22 <sup>8</sup>Cancer Genetics Department, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
- 23 <sup>9</sup>University of Sydney, Sydney, NSW, Australia
- 24 <sup>10</sup>Monash Health Familial Cancer Centre, Clayton, VIC, Australia
- 25 <sup>11</sup>Cancer Genetics service, Liverpool Hospital, Liverpool, NSW, Australia
- 26 <sup>12</sup>Tasmanian Clinical Genetics Service, Royal Hobart Hospital, Hobart, TAS, Australia
- 27 <sup>13</sup>Genetic Services of Western Australia, King Edward Memorial Hospital, Perth, WA, Australia
- 28 <sup>14</sup>Medical School, University of Western Australia, Perth, WA, Australia
- 29 <sup>15</sup>School of Medicine, Curtin University, Perth, WA, Australia
- 30 <sup>16</sup>St Vincent's Cancer Genetics Unit, Sydney, NSW, Australia
- 31 <sup>17</sup>Surgical Professorial Unit, UNSW Clinical School of Clinical Medicine, Sydney, NSW,
- 32 Australia
- <sup>18</sup>Department of Medicine at Royal Melbourne Hospital, Melbourne Medical School, The
- 34 University of Melbourne, Melbourne, VIC, Australia
- <sup>19</sup>Department of Pathology, The Royal Melbourne Hospital, Melbourne, VIC, Australia
- <sup>20</sup>Centre for Epidemiology and Biostatistics, School of Population and Global Health, The
- 37 University of Melbourne, Melbourne, VIC, Australia
- <sup>21</sup>Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale, AZ, USA
- 39 <sup>22</sup>Envoi Specialist Pathologists, Brisbane, QLD, Australia

It is made available under a CC-BY-NC-ND 4.0 International license .

- 40 <sup>23</sup>University of Queensland, Brisbane, QLD, Australia
- 41 <sup>24</sup>Genomic Medicine and Familial Cancer Centre, Royal Melbourne Hospital, Melbourne, VIC,
- 42 Australia
- 43 <sup>25</sup>Colorectal Medicine and Genetics, The Royal Melbourne Hospital, Melbourne, VIC, Australia
- <sup>26</sup>Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia
- 45 *† These authors contributed equally to this work*
- 46 \*Correspondence: <u>romy.walker@unimelb.edu.au</u>
- 47

48 Simple Summary: Lynch syndrome is caused by germline pathogenic variants in the DNA 49 mismatch repair (MMR) genes predisposing carriers to colorectal and endometrial cancer. 50 Genetic testing for Lynch syndrome, in the form of multigene panel testing, frequently identifies 51 variants of uncertain clinical significance (VUS). These VUS have limited clinical actionability 52 and create uncertainty for patients and clinicians regarding their risk of cancer. In this study, we 53 tested carriers of germline VUS for features consistent with Lynch syndrome, namely 1) tumor 54 microsatellite instability/MMR-deficiency, 2) the presence of a somatic second hit in the MMR 55 gene harboring the VUS by tumor sequencing and 3) the presence of MMR-deficiency in normal colonic mucosa crypts or normal endometrial glands. Our findings showed that microsatellite 56 57 instability/MMR-deficiency status and somatic second hits were consistent with MMR variant 58 classifications as determined by the ACMG/InSiGHT framework. In addition to this, the 59 presence of MMR-deficient crypts/glands were consistent with pathogenic variant classification.

60

61 Abstract: Germline pathogenic variants in the DNA mismatch repair (MMR) genes (Lynch syndrome) predispose to colorectal (CRC) and endometrial (EC) cancer. Lynch syndrome 62 63 specific tumor features were evaluated for their ability to support the ACMG/InSiGHT framework in classifying variants of uncertain clinical significance (VUS) in the MMR genes. 64 Twenty-eight CRC or EC tumors from 25 VUS carriers (6xMLH1, 9xMSH2, 6xMSH6, 65 4xPMS2), underwent targeted tumor sequencing for the presence of microsatellite 66 67 instability/MMR-deficiency (MSI-H/dMMR) status and identification of a somatic MMR 68 mutation (second hit). Immunohistochemical testing for the presence of dMMR crypts/glands in 69 normal tissue was also performed. The ACMG/InSiGHT framework reclassified 7/25 (28%) 70 VUS to likely pathogenic (LP), three (12%) to benign/likely benign, and 15 (60%) VUS 71 remained unchanged. For the seven re-classified LP variants comprising nine tumors, tumor 72 sequencing confirmed MSI-H/dMMR (8/9, 88.9%) and a second hit (7/9, 77.8%). Of these LP 73 reclassified variants where normal tissue was available, the presence of a dMMR crypt/gland was 74 found in 2/4 (50%). Furthermore, a dMMR endometrial gland in a carrier of an MSH2 exon 1-6 75 duplication provided further support for upgrade of this VUS to LP. Our study confirmed that identifying these Lynch syndrome features can improve MMR variant classification, enabling 76 optimal clinical care. 77

78

- 79 Keywords: Lynch syndrome, DNA mismatch repair gene variant classification, DNA mismatch
- 80 repair deficient crypts/glands, colorectal cancer, endometrial cancer, variant of uncertain
- 81 significance, DNA mismatch repair gene somatic mutations

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 82 1. Introduction

83 Lynch syndrome is the most common hereditary cancer predisposition syndrome with an 84 estimated carrier frequency in the population of 1 in 280 [1] and a prevalence of up to 5% in 85 colorectal cancer (CRC) or endometrial cancer (EC) affected people [2-5]. Lynch syndrome is 86 caused by germline pathogenic variants in one of the DNA mismatch repair (MMR) genes, 87 MLH1, MSH2, MSH6, PMS2 [6] or by deletions in the 3' end of the EPCAM gene leading to 88 transcriptional silencing of MSH2 [7]. People with Lynch syndrome have an increased risk of not 89 only CRC and EC but also of cancers of the ovaries, stomach, duodenum, bile duct, gall bladder, 90 pancreas, urinary bladder, ureter, kidney, breast, prostate and brain tumors [8]. Current estimates of penetrance for CRC vary by gene and sex but on average approximately one-third to one-half 91 92 of germline MMR pathogenic variant carriers will be diagnosed with CRC by the age of 70 93 [9,10]. Once identified, carriers of MMR gene pathogenic variants can be offered screening via 94 colonoscopy with polypectomy and other opportunities to prevent cancer development or the 95 ability to diagnose Lynch syndrome cancers at an early curable stage [11].

96 The current diagnostic approach to identify carriers of pathogenic MMR variants involves immunohistochemical (IHC) testing of CRC or EC tumors for loss of MMR protein 97 98 expression followed by germline multigene panel testing of the MMR genes [12]. A recurring 99 outcome from genetic tests is the identification of germline variants of uncertain clinical significance (VUS) in one of the MMR genes, reported to occur in 6% of the cases undergoing 100 101 testing for Lynch syndrome [13]. Uncertainty regarding the pathogenicity of a VUS impacts 102 clinical management, as carriers of pathogenic variants receive more intensive clinical care including screening such as colonoscopy, and choice/timing of possible risk reducing surgeries, 103 104 than carriers of benign variants [14]. The American College of Medical Genetics and Genomics 105 (ACMG) has developed standards and guidelines for the interpretation of sequence variants 106 identified in Mendelian disorders [15]. Here, the recommendation is to classify variants into five categories (class 1-5) based on available evidence deriving from variant prevalence in the 107 108 population, in silico effect prediction, functional assays and segregation data, amongst other data 109 sources [15]. Comparably, the International Society for Gastrointestinal Hereditary Tumours 110 (InSiGHT) working group determined InSiGHT criteria to aid with MMR variant classification 111 (https://www.insight-group.org/criteria/, last accessed date: 31<sup>st</sup> of May 2023). In this Bayesian 112 based analysis, variant pathogenicity probabilities derive from tumor characteristics and 113 predetermined combinations of evidence types to predict the variant pathogenicity likelihood 114 [16].

The tumor characteristics used in the InSiGHT criteria to guide MMR variant classification are features commonly observed in individuals diagnosed with Lynch syndrome, such as high levels of microsatellite instability (MSI-H) and MMR-deficiency (dMMR) [17], as determined by MSI polymerase chain reaction (MSI-PCR) and IHC assays, respectively. MSI-PCR and IHC each have their own limitations leading to false positive or false negative testing results [18,19] which impedes accurate classification of MMR variants. MSI-H/dMMR tumors develop in Lynch syndrome when one allele in an MMR gene becomes inactivated by a germline

It is made available under a CC-BY-NC-ND 4.0 International license .

122 pathogenic variant while the other allele becomes inactivated by either a somatic mutation or by 123 loss of heterozygosity (LOH). This acquisition of a somatic second hit, as described by the 124 Knudson two-hit hypothesis [20], results in complete loss of MMR function. As next-generation 125 sequencing (NGS) becomes more widely adopted for precision oncology and diagnostic 126 purposes, the ability to accurately determine MSI-H/dMMR status [21,22] and identify MMR 127 gene somatic mutations/LOH [23] using this methodology is becoming increasingly attractive as 128 a streamlined approach to diagnosing Lynch syndrome. While the strength of both the ACMG 129 guidelines and InSiGHT criteria are the ability to draw on multiple data sources, these may not 130 always be accessible in clinical settings [16]. Therefore, despite important advances, 131 classification of germline variants in the MMR genes remains challenging.

132 A novel finding in Lynch syndrome has been the identification of dMMR in 133 morphologically normal colonic crypts [24–27] or endometrial glands [28,29]. dMMR 134 crypts/glands are specific to people with Lynch syndrome, observed only in carriers and not in 135 people with sporadic MSI-H/dMMR tumors [27]. In people with Lynch syndrome the acquisition 136 of the somatic second hit in normal tissue results in biallelic inactivation of the MMR gene, 137 which is evidenced by loss of MMR protein expression as detected by IHC [24,27], representing 138 the initiation of tumorigenesis. Therefore, the presence of a dMMR crypt/gland is a strong 139 indicator of a germline MMR pathogenic variant. To date, this unique characteristic has not yet 140 been investigated for its potential application in MMR gene variant classification approaches.

141 To be most inclusive of current variant classification parameters, we applied a combination of 142 the ACMG guidelines integrated with the InSiGHT criteria, hereon referred to as the 143 ACMG/InSiGHT framework, for classification of variants in the MMR genes. MMR gene 144 variant classification has undergone substantial progress in the last decade through incorporation 145 of features unique to the Lynch syndrome phenotype. With the evolution of NGS-based 146 diagnostics, including for Lynch syndrome [30,31], the shift from tumor IHC to tumor NGS to 147 determine MSI-H/dMMR status is gaining support. Additionally, evidence of the presence of 148 dMMR crypts/glands has the potential to inform MMR gene variant classification within the 149 ACMG/InSiGHT approach. Thus, in this study, we investigated the role of 1) NGS-based MSI-150 H/dMMR status using an additive feature combination approach as described previously [22], 2) the presence of a somatic second hit (single mutation or LOH) in the MMR gene harboring the 151 152 VUS and 3) the presence of a dMMR crypt/gland in normal colonic or endometrial tissue, in 153 classifying 25 MMR VUS and compared this to their classification status derived from the 154 ACMG/InSiGHT framework. Determination of additional features or approaches to support 155 MMR gene variant classification will improve the diagnosis of Lynch syndrome and the 156 precision prevention of cancer in carriers.

157

#### 158 **2. Materials and Methods**

159 2.1 Patient Cohort

160 Participants were men and women diagnosed with primary CRC or women diagnosed with EC

161 (n=25) who were identified by clinical genetic testing to carry a germline MMR gene VUS as

It is made available under a CC-BY-NC-ND 4.0 International license .

- 162 defined by the clinical testing report and subsequently referred by one of the Family Cancer
- 163 Clinics across Australia to the ANGELS study ("<u>Applying Novel Genomic approaches to Early-</u>
- 164 onset and suspected Lynch Syndrome colorectal and endometrial cancers") between 2018 and
- 165 2022 [32] (test group, n=25 carriers who developed n=28 tumors, Table 1). Cancer-affected
- 166 relatives were recruited where possible to investigate segregation of the VUS. The patient IDs
- 167 used in this manuscript are not known to anyone outside the research group and cannot be used
- 168 to identify study subjects.

	F amily Count	Family ID	R ela tionship	Carrier Count	Carrier ID	Sex	VUS Count	Gene	Variant	Varian t Type	Carrier Status	Tumors Sequenced	Tissue ID	Tissue	Age at Diagnosis	IH C	MLH1 Methylation	Carrier Tumors Tested in this Study
	1	F_051	Index	1	ID_051	F	1	MLH1	c.71_8 Sdel p. Val24_Pro28del	Inframe deletion	Proband - tumor 1	1	EC_051	EC	56-60	M LH1/ PMS 2	N EGATIVE	1
		F_051	Index		ID_0 51	F		MLH1	c.71_85del p. Val24_Pro28del	Inframe deletion	Proband – tu mor 2		B rea st_05 1	Breast	46-50	NT	NT	
		F_051	Index		ID_0 51	F		MLH1	c .71_85de   p. Val24_Pro28de	Inframe deletion	Proband – tu mor 3		Duo_0 51	Duode na l	56-60	NT	NT	
		F_051	Index		10_0 51	F		MLH1	c .71_85de   p.  Va  24_Pro 28de	Inframe deletion	Proband - polyp 1		Polyp1_051	Tubulovillous ade noma	51-55	Normal	NT	
		F_051	Index		ID_0 51	F		MLH1	c .71_85del p. Val24_Pro28del	Inframe deletion	Proband – polyp 2		Po lyp2_05 1	Tubulovillous ade noma	56-60	Normal	NT	
		F_051	Index		10_0 51	F		MLH1	c .71_85de   p.  Va  24_Pro 28de	Inframe deletion	Proband – polyp3		Polyp3_051	Tubulovillous ade noma	56-60	M LH 1*/ PMS 2	NT	
	2	F_161	Index	2	ID_161	F	2	MLH1	c .539_541del p.  Va  180del	Inframe deletion	Proband - tumor 1	2	EC_161	EC	56-60	M LH1/ PMS 2	N EG AT IV E	2
					1		3	MS H6	c.4068_4071d up.p. Lys1358Aspfs*2	Frameshift								
		F_161	Index		10_161			MLH1	c.539_541de1 p.) va 1180d elj	inframe deletion	Proband - tumor 2		CRC_161	CRC	31-35	Normal	NI	
		F_161	Sibling	4	10_16 1-2 In_16 1-2	E N		MUHT	c 539_541de1 p. va hoosel	Inframe deletion	Carrier- Jumor 1		CRC1_161-3	CRC	31-35	NT	NT	
		F_161	Sibling		10_101-5			MINT	c 539 S414el n i Val1804eli	Inframe deletion	Carrier - tumor?		CRC2_161-3	CRC	61-65	MTH1/RMS2	NT	
		E 161	Sibling		ID_101-3			MUHT	c 539 5414e1 n 1/a [1804e]	Inframe deletion	Carrie r- tumo r 3		10.02 161-3	Lung	61-65	NT	NT	
	3	F 176	Index	5	ID 176	F	4	MLH1	c.1594G>C p. G v532Arg	Missense	Proband - tu mor 1	3	CRC 176	CRC	46-50	MLH1/PMS2	NEGATIVE	3
		F 176	Index		ID 176	F		MLH1	c.1594G>C p. Gly532Arg	M is sense	Proband - tumor 2	4	EC 176	EC	51-55	M LH1*/ PMS2	NEGATIVE	
s		F_176	Pare nt	6	ID_176-2	F		MLH1	c.1594G>C p. Gly532Arg	M issense	Carrier		CRC_176-2	CRC	81-85	PMS2	NT	
1CK	4	F_326	Index	7	ID_326	F	5	MLH1	c.1595G>A p. Gly532Asp	M issense	Proband	5	CRC_3 26	CRC	41-45	M LH 1*/ PMS2	N EGATIVE	4
10	5	F_376	Index	8	ID_3 76 <sup>2</sup>	м	6	MS H2	Exon 1-6 duplication	Exon duplication	Proband	6	CRC_3 76	CRC	26-30	MS H2 / MS H6	NT	5
RN	6	F_058	Index	9	ID_0 58 <sup>3</sup>	F	7	MS H2	Exon 1-6 duplication	Exon duplication	Proband - tumor 1	7	EC_058	EC	46-50	MS H2 / MS H6	NT	6
ELV.		F_058	Index		ID_058	F		MS H2	Exon 1-6 duplication	Exon duplication	Proband – tu mor 2		S kin_0 58	S k in	46-50	NT	NT	
HC P		F_0 58	Child	10	ID_058-2	F		MS H2	Exon 1-6 duplication	Exon duplication	Carrier		Po lyp _0 58-2	Sessile serrated ade noma	16-20	NT	NT	
2		F_058	Pare nt	11	ID_058-3	F		MS H2	Exon 1-6 duplication	Exon duplication	Carrie r - tumo r 1		CRC1_058-4	CRC	51-55	NT	NT	
NV.		F_058	Pare nt		ID_058-3	F		MS H2	Exon 1-6 duplication	Exon duplication	Carrier - tumor2		CRC2_058-4	CRC	51-55	NT	NT	
ORD		F_058	Relative	12	ID_058-4	M		MS H2	Exon 1-6 duplication	Exon duplication	Obligate carrier - tumor 1		CRC_058-5	CRC	71-75	NT	NT	
NC		F_058	Relative	13	ID_058-4	F		MS H2	Exon 1-6 duplication	Exon duplication	Carrier		NA NA	linaffected	/1-/5	NT	NT	
8	7	F 149	Index	14	In 149 <sup>4</sup>	M	8	MS H2	Exon 14-15 duplication	Exon duplication	Proband	8	CRC 149	CRC	26-30	MS H2 / MS H6	NT	7
Vus		F 149	Pare nt	15	ID 149-23	F		MS H2	Exon 14-15 duplication	Exon duplication	Carrier		CRC 149-2	CRC	46-50	NT NT	NT	
MR	8	F_138	Index	16	ID_138	м	9	MS H2	c 328 A> C p   Lys110 G m	M is sense	Proband - tumor 1	9	C RC 1_138	CRC	66-70	MS H2 / MS H6	NT	8
≥ is		F_138	Index		ID_138	м		MS H2	c 328 A> C p.  Lys110 Gln	M issense	Proband – tumor 2		C RC 2_138	CRC	76-80	NT	NT	
2ND		F_138	Sibling	17	ID_138-2	м		MS H2	c 328A>C p   Lys110 G m	M is sense	Carrier - tumor 1		5 kin_138-2	S kin   me la noma	41-45	NT	NT	
0B/		F_138	Sibling		ID_138-2	M		MS H2	c 328A>C p. Lys110GIn	M is sense	Carrier - tumor2		CRC_138-2	CRC	61-65	Normal	NT	
PR		F_138	s tolling Index	18	ID 315	E	10	MS HZ	c 1862GNT n i Are6211eui	M IS SE IISE M is se nse	Richand - Lumor 1	10	P411_13 8+2 FC 3.15	Failcleatic	76-80 61-65	MS H2 / MS H6	NT	
		F_315	Index	10	ID_315	F		MS H2	c.1862G>T p. Arg621Leu	M is sense	Proband - tumor 2	10	CRC_3 15	CRC	36-40	NT	NT	_
		F_315	Sibling	19	ID_315-2	F		MS H2	c .1862 G>T p. Arg62 1Leu	M is sense	Carrier – tumor	11	EC_315-2	EC	56-60	MLH1/PMS2*	POSITIVE	10
	10	F_315	Sibling	20	ID_315-2	F		MS H2	c .1862G>T p.  Arg621Leu	M is sense	Carrier - polyp	12	Po lyp_3 15-2	endometrial polyp	56-60	NT MCU12/MCUG	NT	
	10	F_008	Index	20	ID_008	F	11	MS H2	c 2005+3_2005+14081	Splice	Proband - tumor 1	12	lineter 008	li re te r	41-45	NT NT	NT	11
		F 008	Index		ID 008	F		MS H2	c 200 5+3 200 5+ 14de	Splice	Proband - tumor 3		CRC 008	CRC	51-55	NT	NT	
	11	F_132	Index	21	ID_132	F	12	MS H2	c 2060T>C p. Le u687P ro	M issense	Proband	13	CRC_132	CRC	36-40	MS H2 / MS H6	NT	12
	12	F_156	Index	22	ID_156	F	13	MS H6	c.3556+5_3556+8delins p.?	S plice	Proband - tumor 1	14	CRC_1 56	CRC	61-65	M S H6	NT	13
		F_156	Index		ID_156	F		MS H6	c 3 556+5_3 556+8de lins p.?	Splice	Proband - tumor 2	15	EC_156	EC	51-55	MS H6	NT	
	13	F 143	Index	23	D 143	F	14	PM 52	c.137G>T p.(Ser46  e)	S price Missense	Proband	16	N.A EC 143	EC	26-30	PMS2	N I NEGATIVE	14
		F_143	Sibling	25	ID_143-2	M		PM S 2	c.137G>T p. Ser46lle	M issense	Carrier		NA	Unaffected	Un know n	NT	NT	
		F_143	Pare nt	26	ID_143-3	м		PM S 2	c.137G>T p. Ser46lle	M issense	Carrier		NA	U na ffe cte d	Un know n	NT	NT	
		F_143	Relative	27	ID_143-4	F		PM S 2	c.137G>T p. Ser46lk	M issense	Carrier		NA	U na ffecte d	Un know n	NT	NT	
		F_143	Re La tive	28	ID_143-5	F		PMS2 PMS2	c.137GST p.[Ser4618]	MISSERSE Misserse	Carrier		N A	U name cte d	Un know n	NT NT	NT NT	
		F 143	Relative	30	ID 143-7	F		PMS2	c.137G>T p. Ser46lk	Missense	Obligate Carrier		NA	Unaffected	Un known	NT	NT	
		F_143	Relative	31	ID_143-8	F		PM 52	c.137G>T p. Ser46lk	M issense	Carrier		NA	U na ffecte d	Un know n	NT	NT	
N,	14	F_328	Index	32	ID_328	F	15	MLH1	c .1153 C>T p. Arg385C ys	M issense	Proband – tu mor 1	17	CRC_3 28	CRC	41-45	MS H2 / MS H6	NT	15
SL TEF		F_328	Index		ID_3 28	F		MLH1	c.1153C>T p. Arg385C ys	M is se nse	Proband – tu mor 2		B rea st_32 8	Breast	51-55	NT	NT	
R VI	15	F_202	Index	33	ID_202	F	16	MS H2	c.138C>G p. His46Gln	M is sense	Proband - tumor 1	18	EC_2 02	EC	61-65	M S H6	NT	16
MM IHC	16	F_202	Index	34	ID_202	, r	17	MS H2	C.158C2G p. HIS40G III	Missense	Proband - Turnor z	19	CRC 3.95	CRC	36-40	N LH1 / DMS 2	NEGATIVE	17
. 0 .	17	F 089	Index	35	ID 089	F	18	MS H6	c 282 7G>T p. As p943 Tyr	Missense	Proband - tumor 1	20	C RC 1 089	CRC	41-45	MLH1/PMS 2	NEGATIVE	18
NAN' DAN'		F_089	Index		ID_089	F		MS H6	c 2827G>T p. Asp943Tyr	M issense	Proband - tumor 2		C RC 2_089	CRC	41-45	NT	NT	
DRC	18	F_046	Index	36	ID_046	F	19	MS H6	c 2950A>C p. As n984His	M issense	Proband	21	EC_046	EC	66-70	PMS2	N EGATIVE	19
ISCC 1	19	F_263	Index	37	ID_263	F	20	MS H6	c.*85T>A p.?	3'UTR	Proband	22	EC_263	EC	61-65	M LH1*/ PMS2	N EG AT IV E	20
-	20	F_193	Index	38	D_193	M	21	PM S 2	c 2 149 G>A p. Va 717 Me t	M issense	Proband	23	CRC_193	CRC	31-35	MLH1/PMS2	NEGATIVE	21
¥	21	F_170	Index	39	ID_170	F	22	MLH1	CH1/G>T p?	5' UTR	Proband	24	CRC_170	CRC	31-35	Normal	NEGATIVE	22
E III	22	F 240	Index	40	10_111 ID 240	F	25	MS H6 PM S2	r 2335654 n G W7794re	mirame deletion Missense	Proband	25	CRC_111 CRC_240	CRC	36-40	Normal	NEGATIVE	23
MIN	24	F 3 52	Index	42	ID 3 52	M	25	PMS2	c 241G>A p. G u81Lys	Missense	Proband - tumor 1	27	C RC 1 3 52	CRC	56-60	Normal	NT	25
Q.		F_3 52	Index		10_3 52	м		PM S 2	c 241G>A p. G lu81Lys	M issense	Proband - tumor 2	28	C RC 2_3 52	CRC	56-60	MS H2 / MS H 6	NT	
		F_3 52	Index		ID_3 52	м		PM S 2	c 241G>A p. Glu81Lys	M issense	Proband – tu mor 3		B ra in_3 52	Gliob las to ma	51-55	NT	NT	

169

- Table 1. List of carriers of a germline DNA mismatch repair variant of uncertain clinical
  significance and their cancer-affected status that were included in this study. Abbreviations: ID,
  identification number; F, female; M, male; VUS, variant of uncertain clinical significance; CRC,
  colorectal cancer; EC, endometrial cancer; IHC, immunohistochemistry; NA, not applicable; NT,
- 174 not tested; UTR, untranslated region.
- 175 + Indicates heterogeneous / patchy loss of DNA mismatch repair protein expression by IHC

- <sup>1</sup>Family members (F\_161) were only tested for the germline *MLH1* c.539\_541del p.(Val180del)
- variant and not for the concomitant *MSH6* c.4068\_4071dup p.(Lys1358Aspfs\*2) variant
- 178 <sup>2</sup> The parents (ID\_376-2 and ID\_376-3) from carrier ID\_376 were tested for the germline MSH2
- 179 exon 1-6 duplication and were found to be wildtype
- <sup>3</sup> The sister (ID\_058-3) and relative (ID\_058-7) from carrier ID\_058 were tested for the germline
- 181 *MSH2* exon 1-6 duplication and were found to be wildtype
- <sup>4</sup> Participant ID\_149 carries a germline MSH2 exon 14-15 duplication and a concomitant
   germline *POLE* c.1708C>A p.(Leu570Met) variant
- <sup>5</sup> The mother (ID\_149-2) from carrier ID\_149 was tested for the familial germline *MSH2* exon
- 185 14-15 duplication and *POLE* c.1708C>A p.(Leu570Met) variants, however, was found to only 186 carry the *MSH2* germline VUS
- 187

188 A biopsy or resection tumor tissue specimen was collected from each participant. Normal 189 colonic mucosa or normal endometrium tissue were collected where possible. Pedigree 190 information was collected during clinical work-up and segregation of the MMR VUS in family 191 members was performed via Sanger sequencing as part of this study. A group of CRC- or EC-192 affected MMR pathogenic variant carriers (n=19) or non-carriers of a germline MMR pathogenic 193 variant or VUS (n=20) who were participants of the Australasian Colorectal Cancer Family 194 Registry (ACCFR) were included as reference groups, where n=37 underwent targeted panel 195 sequencing or whole exome sequencing as shown in Table S1. The molecular and phenotypic 196 characterization of these individuals and their tumors from the ANGELS [22,32,33] and the 197 ACCFR [2,34-36] have been described previously. All studies were approved by the Human 198 Research Ethics Committees at The University of Melbourne (HREC#1750748) and hospitals 199 governing participating family cancer clinics. Written informed consent was obtained from all 200 participants.

201

#### 202 2.2 Immunohistochemical Testing for DNA Mismatch Repair Protein Expression

For the 25 MMR VUS carriers, IHC of tumor tissue was derived from either the diagnostic pathology report or from testing performed by this study. For this study, the Ventana DISCOVERY ULTRA automated stainer (Ventana Medical Systems Inc., Oro Valley, United States) was used with anti-MLH1 (M1), anti-MSH2 (G219-1129), anti-MSH6 (SP93) mouse monoclonal and anti-PMS2 (A16-4) rabbit monoclonal primary antibodies (Roche Diagnostics, Basel, Switzerland) and tested on a 4µM tissue section. All staining protocols were performed following the manufacturer's protocol (Roche Diagnostics).

To detect dMMR colonic crypts or endometrial glands, IHC was performed on  $4\mu$ M sections from a tissue block containing non-tumor-adjacent normal colonic mucosa or endometrium from the resection margins. Twenty serial  $4\mu$ M sections were cut to a depth of 80 $\mu$ M with the 1<sup>st</sup>, 10<sup>th</sup> and 19<sup>th</sup> slide stained for the MMR protein that was concordant with the MMR gene harboring the VUS. If no dMMR crypt/gland was identified, a further twenty  $4\mu$ M sections were cut and screened. This process was repeated up to three times with a maximum of

It is made available under a CC-BY-NC-ND 4.0 International license .

3x80µM sections of tissue screened. When a dMMR crypt/gland was identified, the subsequent 216 section (2<sup>nd</sup>, 11<sup>th</sup> or 20<sup>th</sup> slide) was stained for the unaffected MMR gene as a control for 217 218 artefactual loss of expression. For example, if an MSH2-deficient crypt/gland was identified, the 219 next slide was stained for MLH1 protein expression. All dMMR crypts/glands identified in this 220 study were independently confirmed by two senior pathologists (CR and RP), with 100% 221 concordance in classifying stained slides as positive or negative for dMMR crypts/glands. Six 222 normal colonic mucosa and six normal endometrial tissue samples were available for a total of 223 12 VUS carriers.

224

#### 225 2.3 Tumor MLH1 Methylation Testing Assays

226 Testing for *MLH1* gene promoter methylation on formalin-fixed paraffin embedded (FFPE) 227 tissue DNA was performed as previously described [22,33]. Briefly, two independent MLH1 228 methylation assays, namely MethyLight [2,34] and MS-HRM (methylation-sensitive high 229 resolution melting assay) [37], were used to test the same tumor DNA sample alongside a set of 230 DNA standards (0% - 100% methylation) and no-template (negative) controls. Bisulfite conversion of tumor DNA was performed using the EZ DNA Methylation-Lightning<sup>TM</sup> Kit 231 232 (Zymo Research, Irvine, United States). For MethyLight, *MLH1* methylation was quantitatively 233 reported based on the percentage of methylated reference (PMR) calculations [34], where tumors with a PMR  $\geq 10\%$  were considered "positive" [2,34]. For MS-HRM, the MeltDoctor<sup>TM</sup> HRM 234 235 Reagent Kit (Thermo Fisher Scientific, Massachusetts, United States) was used where tumors 236 demonstrating  $\geq$ 5% were considered *MLH1* methylation "positive".

237

#### 238 2.4 Next-Generation Sequencing

239 All available FFPE tumor tissue DNA (n=28) and matched blood-derived DNA samples from 25 240 MMR VUS carriers (Table 2) underwent targeted multigene panel sequencing using the panel 241 capture previously described [22,33]. This customized panel incorporated 297 genes, including 242 the MMR and EPCAM genes, as well as other established hereditary CRC and EC genes and the 243 BRAF p.V600E mutation (2.005 megabases). Library preparation was performed using the SureSelect<sup>TM</sup> Low Input Target Enrichment System from Agilent Technologies (Santa Clara, 244 245 California, United States) using standard procedures. The median on-target coverage for the 246 panel sequenced test tumors was 906 (interquartile range = 763 - 1099) for the tumor DNA and 247 154 (interquartile range = 128 - 172) for blood-derived DNA samples. Panel libraries were 248 sequenced on an Illumina NovaSeq 6000 (San Diego, California, United States) comprising 150

base pair (bp) paired end reads performed at the Australian Genome Research Facility.

												1								
	_	_						Incorporation of Tu	mor Data fro	m this Study						Incorporatio	n of External Tu	mor Data		
	#	Gene	Variant	Variant Type	ClinVar Variant ID	gnomAD (<1 in 50,000 alleles)	Age at Diagnosis	MSI/MMR Status	Tumor BRAF V600E Mutation Status	Tumor <i>MLH1</i> Methylation Status	ІНС	Total No. of Tumors with IHC Concordant to Germline VUS	Total No. of Tumors with IHC Discordant to Germline VUS	Total No. of Families with Germline MMR VUS Tested	Prior Probability for Pathogenicity (MAPP / PP2 score)	Tumor Characteristics Odds of Pathogenicity	Functional Data	Segregation Odds Ratio	SpliceAI Delta Score	ACMG/InSiGHT Classification
z	1	MLH1	c.71_85del p.(Val24_Pro28del)	Inframe deletion	NA	0	56-60	MSI-H / dMMR (6/6)	WT	Negative	MLH1/PMS2	1	0	1	NA	0.41	None	NA	0.02	Class 3: VUS
TER	2	MLH1	c.539_541del p.(Val180del)	Inframe deletion	185186	0	56-60	MSI-H / dMMR (6/6)	WT	Negative	MLH1/PMS2	1	0	1	NA	0.41	None	NA	0.01	Class 3: VUS
IHC PAT	3	MLH1	c.1594G>C p.(Gly532Arg)	Missense	NA	0	46-50, 51-55	MSI-H / dMMR (5/6) (1x), MSI-H / dMMR (6/6) (1x)	WT (2x)	Negative (2x)	MLH1 <sup>*</sup> /PMS2 (1x), MLH1/PMS2 (1x)	2	0	1	0.96	6.52	None	NA	0.01	Class 3: VUS
2	4	MLH1	c.1595G>A p.(Gly532Asp)	Missense	976474	0	41-45	MSI-H / dMMR (5/6)	WT	Negative	MLH1/PMS2	3	0	5	0.96	153.04	None	1.96	0.01	Class 4: LP
NT SS	5&	6 MSH2	Duplication exon 1-61	Exon duplication	NA	0	26-30, 46-50	MSI-H / dMMR (6/6) (2x)	WT (2x)	NT	MSH2/MSH6 (2x)	2	0	2	NA	42.51	None	NA	NA	Class 3: VUS
DA LC	7	MSH2	Duplication exon 14-15	Exon duplication	NA	0	26-30	MSI-H / dMMR (6/6)	WT	NT	MSH2/MSH6	1	0	1	NA	6.52	None	NA	NA	Class 4: LP
őğ	8	MSH2	c.328A>C p.(Lys110GIn)	Missense	127642	0.00000398	66-70	MSI-H / dMMR (6/6)	WT	NT	MSH2/MSH6	1	0	1	0.06	4.06	None	NA	0.01	Class 3: VUS
Ň	9	MSH2	c.1862G>T p.(Arg621Leu)	Missense	218040	0.0000319	61-65	MSI-H / dMMR (6/6)	WT	NT	MSH2/MSH6	5	0	5	0.85	1103.14	None	1.32	0	Class 4: LP
SCI	10	MSH2	c.2005+3_2005+14del	Splice	90842	0	51-55	MSI-H / dMMR (6/6)	WT	NT	MSH2/MSH6	2	0	2	0.26	16.48	None	1.44	0.57	Class 4: LP
N N	11	MSH2	c.2060T>C p.(Leu687Pro)	Missense	90873	0	36-40	MSI-H / dMMR (6/6)	WT	NT	MSH2/MSH6	1	0	>12	0.96	6.52	None	NA	0	Class 4: LP
MR	12	MSH6	c.3556+5_3556+8delins	Splice	NA	0	61-65	MSI-H / dMMR (5/6)	WT	NT	MSH6	3	0	3	0.26	66.92	None	NA	0	Class 4: LP
Σ	13	PMS2	c.137G>T p.(Ser46lle)	Missense	9245	0.000163	26-30	MSI-H / dMMR (6/6)	WT	Negative	PMS2	2	0	2	0.939	0.65	None	3.083	0.03	Class 4: LP
웃	14	MLH1	c.1153C>T p.(Arg385Cys)	Missense	89653	0.0000597	41-45	MSI-H / dMMR (6/6)	WT	NT	MSH2/MSH6	0	1	2	0.937	0.01	None	9.45	0.03	Class 3: VUS
I O I	15	MSH2	c.138C>G p.(His46GIn)	Missense	90654	0.000218	61-65	MSI-H / dMMR (3/6)	WT	NT	MSH6	1	3	4	0.74	0.00014	None	0.14	0	Class 2: LB
SLED	16	MSH2	c.668T>C p.(Leu223Pro)	Missense	408456	0	36-40	MSI-H / dMMR (6/6)	WT	Negative	MLH1/PMS2	0	1	1	0.525	0.11	None	NA	0	Class 3: VUS
N A B	17	MSH6	c.2827G>T p.(Asp943Tyr)	Missense	142495	0.000046	41-45	MSI-H / dMMR (6/6)	WT	Negative	MLH1/PMS2	0	1	1	0.05	0.11	None	NA	0	Class 3: VUS
N N N	18	MSH6	c.2950A>C p.(Asn984His)	Missense	186492	0.0000479	66-70	MSI-H / dMMR (4/6)	WT	Negative	PMS2	0	1	1	0.005	0.11	None	NA	0	Class 3: VUS
≥ 2 E	19	MSH6	c.4068_4071dup p.(Lys1358Aspfs*2)	Frameshift	89518		56-60	MSI-H / dMMR (6/6)	WT	-	MLH1/PMS2	1	0	1	NA	4.06	None	NA	0.1	Class 2: LB
PA	20	MSH6	c.*85T>A	3' UTR	89155	0.00786	61-65	MSI-H / dMMR (5/6)	WT	Negative	MLH1*/PMS2	0	4	4	0	0	None	NA	0	Class 1: B
ā	21	PMS2	c.2149G>A p.(Val717Met)	Missense	41709	0.000758	31-35	MSI-H / dMMR (5/6)	WT	Negative	MLH1/PMS2	2	0	2	0.595	26.47	None	0.308	0	Class 3: VUS
CLOSS	22	MLH1	c117G>T	5' UTR	344901	0	31-35	MSI-H / dMMR (3/6)	wт	NT	Normal	0	1	1	NA	0.11	None	NA	0.07	Class 3: VUS
± 2	23	MSH6	c.1153_1155del p.(Arg385del)	Inframe deletion	89177	0	36-40	MSI-H / dMMR (5/6)	WT	NT	Normal	1	1	4	0.5	0.46	None	15.22	0	Class 3: VUS
1MF	24	PMS2	c.2335G>A p.(Gly779Arg)	Missense	127778	0.00000799	26-30	MSS / pMMR (1/6)	WT	Negative	Normal	1	0	1	0.96	0.11	None	NA	0.03	Class 3: VUS
NON	25	PMS2	c.241G>A p.(Glu81Lys)	Missense	182817	0.0000159	56-60	MSI-H / dMMR (5/6) (1x), MSS / pMMR (1/6) (1x)	WT (2x)	NT	MSH2/MSH6 (1x), Normal (1x)	0	2	2	0.045	0.02	None	NA	0	Class 3: VUS

250

Table 2. Display of the data used to implement the ACMG/InSiGHT framework for final DNA mismatch repair variant of uncertain
 significance classification. Abbreviations: MSI, microsatellite instability; MSS, microsatellite stable; MMR, DNA mismatch repair;
 dMMR, DNA mismatch repair deficiency; pMMR, DNA mismatch repair proficiency; WT, wildtype; IHC, immunohistochemistry;
 MAPP, multi-variate analysis of protein polymorphisms; PP2, PolyPhen-2.1; VUS, variant of uncertain clinical significance; LB,
 likely benign; LP, likely pathogenic; NA, not applicable; NT, not tested.

256 + Indicates heterogeneous / patchy loss of DNA mismatch repair protein expression by IHC

<sup>1</sup> Two unrelated families (F\_058 and F\_376) who carry the *MSH2* exon 1-6 duplication were grouped together for the purposes of the

258 ACMG/InSiGHT classification, however, at this stage without further investigation, it remains unknown if the breaking points of the

259 variants identified in each family are in the same location

<sup>2</sup> Multiple entries documented in Ambry Genetics (https://www.ambrygen.com/, last accessed date: 23rd of May 2023)

261

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 262 2.5 Bioinformatics Pipeline

263 Adapter sequences were trimmed from raw FASTO files using trimmomatic (v.0.38) [38] and 264 aligned to the GRCh37 human reference genome using Burrows-Wheeler-Aligner (v.0.7.12) to 265 generate BAM files. Germline and somatic single nucleotide variants and somatic insertions / 266 deletions (INDELs) were called using Strelka (v.2.9.2., Illumina, San Diego, California, United 267 States) and Mutect2 (v.0.5) using the recommended workflows [39,40]. Tumor mutational 268 signatures (TMS) were calculated using the pre-defined set of 18 small (1-50bp) 269 insertions/deletions signatures published on COSMIC (ID) as (https://cancer.sanger.ac.uk/signatures/, last accessed date: 13<sup>th</sup> of January 2023, v.3.2) [41]. All 270 variants were restricted to the panel capture region and filtered based on PASS variants called by 271 272 both Strelka and Mutect2. All variants were further filtered on a minimum depth of 50bp for 273 normal/blood and tumor samples with a minimum variant allele frequency of 10% [32]. For 274 variant calling, the following RefSeq transcripts were used (MLH1: NM\_000249.3, MSH2: 275 NM\_000251.2, MSH6: NM\_000179.2 and PMS2: NM\_000535.5). The MMR genes were 276 interrogated for somatic mutations, including single somatic mutations (e.g. missense, nonsense, 277 insertion, deletion, frameshift variant type) and LOH, in the same gene as the germline MMR 278 VUS. LOH across the MMR genes were called using LOHdeTerminator (v.0.6, 279 https://github.com/supernifty/LOHdeTerminator). The pathogenicity of somatic MMR mutations were determined using the Varsome database [42] (https://varsome.com/, last accessed date: 13<sup>th</sup> 280 281 of January 2023), which categorizes variants into the ACMG classification system. All likely 282 pathogenic/pathogenic MMR mutations were manually confirmed in BAM files using the 283 Integrative Genomics Viewer (v.2.3) [43].

284

285 2.6 Determination of Tumor Microsatellite Instability and Mismatch Repair Deficiency

286 Panel sequenced tumors were assessed for evidence of MSI-H/dMMR using: 1) four independent 287 MSI detection tools, namely MSMuTect [44], MANTIS [45], MSIseq [46] and MSISensor [47], 288 2) INDEL count and 3) the combination of ID2 TMS with ID7 TMS (TMS ID2+ID7) [32] as 289 described in Walker et al. 2023 [22]. Overall tumor MSI-H/dMMR status was determined by 290 combining these six features (using an additive feature combination approach), where a tumor 291 with any 3 or more of these 6 features with positivity for dMMR was considered to be MSI-292 H/dMMR [22]. This approach has been shown to be the most robust across whole-exome 293 sequencing and panel assays as well as across CRC and EC tumors, while presenting with the 294 highest prediction accuracy to differentiate dMMR from pMMR (MMR-proficient) tumors [22].

295

296 2.7 Classifying MMR Variants Using a Combination of Existing Methodologies

We used a combination of the ACMG [15] and InSiGHT [16] criteria, hereon referred to as the ACMG/InSiGHT framework, for improved and contemporary variant classification. Briefly, the

299 features assessed are displayed in **Table 2**, including:

It is made available under a CC-BY-NC-ND 4.0 International license .

- Rarity of MMR variant (the rarer a variant, the more likely the variant will not be present in healthy controls, with <1 in 50,000 alleles indicating MMR variant rarity in gnomAD using the non-cancer dataset,);</li>
- Incorporation of tumor characteristics generated by this study, including age of diagnosis,
   tumor NGS-derived MSI-H/dMMR status, tumor *BRAF* V600E mutation status, tumor
   *MLH1* methylation status and MMR IHC result;
- Prior probability scores calculated for missense variants using the *in silico* prediction tools Multi-variate Analysis of Protein Polymorphisms [48] and PolyPhen-2.1 [49] (pre-computed prior probabilities with a score of >0.68 and ≤0.81 indicate variant pathogenicity as determined in <u>https://hci-priors.hci.utah.edu/PRIORS/</u> (last accessed date: 18<sup>th</sup> of July 2023);
- Tumor characteristics, either generated from this study or available from external public
   data, for the same variant were combined to generate a tumor odds pathogenicity score
   [50,51];
- Evidence of functional effect on protein structure (e.g., ClinVar, https://www.ncbi.nlm.nih.gov/clinvar/, last accessed date: 1<sup>st</sup> of June 2023);
- Co-segregation of variant with disease phenotype with a combined Bayes Likelihood
   Ratio >18.7 in two or more families [16] (e.g., COsegregation v.2: <u>https://fengbj-</u>
   <u>laboratory.org/cool2/manual.html</u>, last accessed date: 1<sup>st</sup> of June 2023);
- Predicted splicing effect using SpliceAI (with a delta score of >0.2 indicating pathogenicity) (<u>https://spliceailookup.broadinstitute.org/</u>, last accessed date: 1<sup>st</sup> of June 2023) [52].
- These parameters were cumulatively considered for final MMR variant classification and variants were categorized into the recommended five-tier ACMG classifications (class 5 pathogenic (P), class 4 likely pathogenic (LP), class 3 variant of uncertain significance (VUS), class 2 likely benign (LB), class 1 benign (B)) [15]. The final ACMG/InSiGHT classification for each of the 25 MMR VUS was then assessed for concordance with the tumor NGS-derived MSI-H/dMMR status, somatic second hit and dMMR crypt/gland testing results.
- 329

#### **330 3. Results**

#### 331 3.1 Characteristics of Patients with MMR VUS

332 An overview of the study design is shown in Figure 1. A total of 24 carrier families with 25 333 unique germline MMR VUS were included in the study comprising VUS in *MLH1* (n=6), *MSH2* 334 (n=9), MSH6 (n=6) and PMS2 (n=4) with 14/25 (56%) VUS resulting in missense changes 335 (Table 1, Table 2). Testing for segregation of the VUS in relatives identified an additional 18 336 carriers, where the cancer-affected status of each of the 42 germline VUS carriers (probands and 337 relatives) included in the study are shown in **Table 1**. The tumor type and age at diagnosis 338 (ranging from 15-20 and 81-85 years) for each of the carriers are listed in **Table 1**, where 16/42 339 (38.1%) carriers developed multiple tumors. The pedigree for each of the VUS carrying families

It is made available under a CC-BY-NC-ND 4.0 International license .

- 340 can be requested from the corresponding author upon reasonable request. For 25/42 (59.5%)
- 341 VUS carriers in this study, we tested one or more tumors (**Table 1**). The pattern of loss of MMR
- 342 protein expression by IHC was concordant with the MMR gene harboring the VUS in 13/25
- 343 (52%) of the cases, discordant in 8/25 (32%) of the cases, while for a further four carriers (16%),
- no loss of MMR protein expression by IHC was reported (pMMR) (Table 1, Table 2).



Comparison of ACMG/InSiGHT framework with novel Lynch syndrome related tumor features

345

Figure 1. Overview of study design. Schema presenting the study inclusion criteria, the
breakdown of the germline MMR VUS distribution and the testing assays applied. *Abbreviations*: CRC, colorectal cancer; EC, endometrial cancer; MMR, DNA mismatch repair;
VUS, variant of uncertain clinical significance; IHC, immunohistochemistry; MSI, microsatellite
instability; MSI-H, high levels of microsatellite instability; MSS, microsatellite stable; dMMR,
DNA mismatch repair deficiency; pMMR, DNA mismatch repair proficiency; ACMG, American
College of Medical Genetics and Genomics; InSiGHT, International Society for Gastrointestinal

- 353 Hereditary Tumours.
- 354

#### 355 3.2 Variant Classification Using the ACMG/InSiGHT Framework

- 356 The re-classification of the 25 MMR VUS based on the ACMG/InSiGHT framework (see
- 357 Methods above) are shown in **Table 2**. A total of 10/25 (40%) VUS were reclassified, with seven

It is made available under a CC-BY-NC-ND 4.0 International license .

358 VUS (28%) reclassified as likely pathogenic (class 4), all of which showed a concordant pattern 359 of MMR protein loss of expression by IHC. Two out of 25 (8%) were reclassified as likely 360 benign (class 2) and one VUS was reclassified as benign (class 1), where each of the three LB/B 361 variants had a pattern of MMR protein loss that was discordant with the MMR gene harboring 362 the variant (Table 2). None of the VUS were categorized as pathogenic (class 5). For the 363 remaining 15 VUS, the additional information provided by this study did not change their classification as a class 3 variant. Of these, six VUS were concordant with the observed IHC 364 365 pattern of loss, five VUS were discordant to the observed IHC pattern of loss, with four VUS 366 displaying no MMR protein loss by IHC (pMMR) (Table 2).

367

## 368 3.3 Determining Microsatellite Instability / DNA Mismatch Repair Deficiency using Tumor 369 Sequencing Data

370 To assess whether tumor features and somatic profiles generated using tumor panel sequencing 371 could inform MMR VUS classification, tumor features associated with Lynch syndrome were 372 assessed on 28 tumors collected from the 25 VUS carriers in this study (Table 1), and compared 373 with a reference group of dMMR tumors from known germline MMR pathogenic variant carriers 374 (n=16) and pMMR tumors from non-MMR carriers (n=18) that previously underwent tumor 375 panel sequencing (Table S1). The aim was to determine tumor MSI/MMR status from NGS by 376 applying the previously described additive feature combination approach [22] and compare this 377 with the observed MMR IHC status. For the reference group of tumors, the MSI/MMR status 378 from tumor sequencing was 100% concordant with the MMR IHC dMMR or pMMR result. As 379 expected for the Lynch syndrome tumors, the pattern of MMR protein loss was concordant with 380 the MMR gene harboring the germline pathogenic variant and all were MSI-H/dMMR by tumor 381 sequencing (Table S1, Figure S1A). In the test group of 28 tumors from 25 VUS carriers, 25/28 382 were classified as MSI-H/dMMR from tumor sequencing, of which 23/25 (92%) were dMMR by 383 MMR IHC (Table 3, Figure S1B). Three tumors were classified as MSS/pMMR from tumor 384 sequencing with two (66%) of these also confirmed to be pMMR by MMR IHC (Table 3, 385 Figure S1B). All 7 of the VUS reclassified by ACMG/InSiGHT framework to LP had at least 386 one tumor that was MSI-H/dMMR (Table 3). There were an additional 8 tumors from 7 VUS 387 carriers that were not reclassified by ACMG/InSiGHT framework that were MSI-H/dMMR from 388 tumor sequencing and demonstrated loss of the MMR protein/s concordant with the MMR gene 389 harboring the VUS (Table 3).

It is made available under a CC-B	Y-NC-ND 4.0 International license
-----------------------------------	-----------------------------------

				Germline MMR	vus			Tumor Molecula	ır Data	Lynch Sync	Irome Associated Tissu	e Features	
#	Carrier ID	Tissue ID	Gene	Base Change	Prote in Change	ACMG/ InSiGHT Classification	Tis su e	IHC	<i>MLH1</i> Methylation	MSI/MMR Status by Additive Feature Approach	Presence of a Somatic Second Hit in MMR Gene Harboring VUS	Presence of a Somatic Mutation NOT in MMR Gene Harboring VUS	Final Tumour Class if ication
1	ID 326	CRC 326	MLH1	c.159 5G >A	p.   G   y532 As p	Class 4: LP	CRC	MLH1*/PMS2	NEG ATIVE	MSI-H / d MMR   5/6	1x LOH  MLH1	No ne	dMMR - VUS + 2nd hit  MLH1
2	ID_149	C RC_149	MSH2	Exon 14-15 duplication	p.?	Class 4: LP	CRC	MS H2 /MS H6	NT	MSI-H / d MMR   6/6	1x m ut.  MSH2	None	dMMR · VUS + 2 nd hit  M SH2
3	ID_315	EC_315	MS H2	c.1862G>T	p. Arg621Leu	Class 4: LP	EC	MS H2 /MS H6	NT	MSI-H / dMMR   6/6	1x mut.   <i>MSH2</i>	1x mut.   <i>MSH6</i>   and 1x mut.   <i>PMS2</i>	dMMR - VUS + 2nd hit  MSH2
4	ID_315-2	EC_315-2	MSH2	c.1862G>T	p. Arg621Leu	Class 4: LP	EC	MLH1/PMS2*	PO SI TI VE	MSS / pMMR  0/6	None	No ne	dMMR - MLH1 methylation
5	ID_008	EC_008	MS H2	c.2005+3_2005+14del	p.?	Class 4: LP	EC	MS H2 /MS H6	NT	MSI-H / dMMR  6/6	1x LOH  MSH2	1x mut.   <i>MLH1</i>   and 1x mut.   <i>PMS2</i>	dMMR - VUS + 2 nd hit   <i>M SH2</i>
6	ID_132	C RC_132	MS H2	c.206 0T>C	p. Le u6 87 Pro	Class 4: LP	CRC	MS H2 /MS H6	NT	MSI-H / d MMR   6/6	1x m ut.  MSH2	No ne	dMMR - VUS + 2 nd hit  MSH2
7	ID_156	CRC_156	MS H6	c.3556+5_3556+8de lins	p.?	Class 4: LP	CRC	MS H6	NT	MSI-H / d MMR   5/6	1x m ut.  MSH6	No ne	d MMR - VUS + 2 nd hit   <i>M SH6</i>
8		EC_156				Class 4: LP	EC	MS H6	NT	MSI-H / dMMR  3/6	None	None	d MMR - VUS   <i>MSH</i> 6
9	ID_143	EC_143	P MS 2	c.137G>T	p. Ser46Ile	Class 4: LP	EC	PMS2	NEG ATIVE	MSI-H / dMMR  6/6	2 x m ut.   <i>PMS2</i>	2x mut.   <i>MSH2</i>  , 2x mut.   <i>MSH6</i>   and 1x mut.   <i>MLH1</i>	dMMR - VUS + 2nd hit   <i>PMS2</i>
10	ID 1611	EC 161	MLH1	c 539 541del	n iVal180deli	Class 3: VIIS	FC	MLH1/PMS2	NEG ATIVE	MSILH / dMMR 16/61	1 x mut  M/H1	None	dMMR, VIIS + 2 nd bit  M/H1
10	ID 051	EC 051	MLH1	c.71 85del	p. Val24 Pro28del	Class 3: VUS	EC	MLH1/PMS2	NEGATIVE	MSI-H / dMMR   6/6	1x IOH  MLH1   and 1x mut.  MLH1	1x mut. (MSH6)	d MMR · VUS + 2nd hit  MLH1
12	ID 176	CRC 176	MLH1	c.159 4G >C	p.IGIv532Arei	Class 3 : VUS	CRC	MLH1/P MS2	NEG ATIVE	MSI-H / dMMR   6/6	1x LOH  MLH1	1x mut.  MSH6	dMMR · VUS + 2nd hit  MLH1
13	_	EC 176				Class 3 : VUS	EC	MLH1*/PMS2	NEG ATIVE	MSI-H / d MMR   5/6	2 x m ut.  MLH1	1x mut.  MSH6	dMMR · VUS + 2nd hit  MLH1
14	ID 058	EC 058	MSH2	Exon 1-6 duplication	p.?	Class 3 : V US	EC	MS H2 /MS H6	NT	MSI-H / dMMR   6/6	1x LOH  MSH2	None	dMMR · VUS + 2 nd hit   MSH2
15	ID 138	CRC 138	MS H2	c.328A>C	p. Lys 110G ln	Class 3: VUS	CRC	MS H2 / MS H6	NT	MSI-H / dMMR   6/6	2x mut.  MSH2	2xmut.  MSH6	dMMR • VUS + 2 nd hit  MSH2
16	ID 170	CRC 170	MLH1	c117G>T	p.?	Class 3 : V US	CRC	Normal	NEG ATIVE	MSI-H / dMMR   3/6	1x LO H   MLH1	None	dMMR · VUS + 2 nd hit  MLH1
17	ID_111	CRC_111	MS H6	c.1153_1155del	p. Arg385del	Class 3 : V US	CRC	Normal	NT	MSI-H / d MMR   5/6	1x LO H  MSH6	None	dMMR · VUS + 2 nd hit  M SH6
18	ID_376	C RC_376	MS H2	Exon 1-6 duplication	p.?	Class 3: VUS	CRC	MS H2 / MS H6	NT	MSI-H / dMMR   6/6	None	1x mut.   <i>MSH6</i>   and 1x mut.   <i>PMS2</i>	d MM R - VUS   <i>M SH2</i>
19	ID_328	C RC_328	MLH1	c.1153C>T	p. Arg385Cys	Class 3 : V US	CRC	MS H2 /MS H6	NT	MSI-H / dMMR   6/6	None	1x LO H   <i>MSH2</i>   and 1x mut.   <i>MSH2</i>	dMMR - double somatic   <i>MSH2</i>
20	ID_395	C RC_395	MS H2	c.668T>C	p. Leu223Pro	Class 3 : VUS	CRC	MLH1/PMS2	N EG ATIVE	MSI-H / dMMR   6/6	None	1x LO H   <i>MLH1</i>   and 1x m ut.   <i>MLH1</i>	dMMR - double somatic   MLH1
21	ID_089	C RC_089	MS H6	c.2827G>T	p. As p943Tyr	Class 3 : VUS	CRC	MLH1/PMS2	NEG ATIVE	MSI-H / dMMR   6/6	None	1x LO H   <i>MLH1</i>   and 2x mut.   <i>MLH1</i>	d MMR - double somatic   MLH1
22	ID_046	EC_046	MS H6	c.2950A>C	p. As n9 84 His	Class 3 : VUS	EC	PMS2	NEG ATIVE	MSI-H / d MMR   4/6	1x mut.  MSH6	2x mut.  PMS2	dMMR - double somatic  PMS2
												2x mut.   <i>MSH2</i>  , 2x mut.   <i>MLH1</i>   and 1x	
23	ID_3 52 <sup>2</sup>	CRC2_352	P MS 2	c.241G>A	p. Glu81Lys	Class 3 : V US	CRC	MS H2 /MS H6	NT	MSI-H / d MMR   5/6	None	m ut .   MSH6	dMMR - double somatic   MSH2
24	ID_193	C RC_193	P MS 2	c.2149G>A	p. Va  7 17 Met	Class 3 : VUS	CRC	MLH1/PMS2	NEG ATIVE	MSI-H / d MMR   5/6	None	2x m ut.  MLH1	dMMR - double somatic   MLH1
												1x LO H  MLH1   and	
25	ID_263	EC_263	MS H6	C.1851>A	p./	Class 1: B	EC EC	MCH17PMS2	IN EGATIVE	MSI-H / dMMR   5/6	1x mut. MSH6	1x mut.  MLH1 2x mut.  MSH5	d WINK - double somatic   MLH1
20	10_202	000.040	NIS HZ	00000	p.(mis 40 0 m)	Class Z; LB		IVID FID			ak mut, perartz	ZA III UL (MAJATO)	
27	10_240	<u>CKC</u> 240	PIVIS2	C.233 5G>A	p. GIV//9Arg	Class 3 : VUS	CRC	Normal	NEGATIVE	MSS / pMMR  0/6	None	None 2x mut M(H2 Land	prviMR
28	ID_3 52 <sup>2</sup>	CRC1_3 52	P MS 2	c.241G>A	p. Glu81Lys	Class 3 : V US	CRC	Normal	NT	MSS / pMMR  1/6	None	2x mut.   <i>MSH6</i>	pMMR
29	ID_161 <sup>1</sup>	EC 161	MS H6	c.4068 4071dup	p. Lys 13 58As pfs * 2	Class 2:LB	EC	MLH1/PMS2	N EG ATIVE	MSI-H / d MMR   6/6	None	1x m ut.   <i>MLH1</i>	VUS benign

390

391 **Table 3**. Overview of targeted tumor sequencing results from the test group including sequenced 392 family members. Abbreviations: ID, identification number; CRC, colorectal cancer; EC, 393 endometrial cancer; LP, likely pathogenic; VUS, variant of uncertain clinical significance; LB, 394 likely benign; B, benign; IHC, immunohistochemistry; MMR, DNA mismatch repair; MSI, 395 microsatellite instability; MSI-H, high levels of microsatellite stability; MSS, microsatellite 396 stable; dMMR, DNA mismatch repair deficient; pMMR, DNA mismatch repair proficient; LOH, 397 loss of heterozygosity; mut., single somatic mutation; NT, not tested.

398 + Indicates heterogeneous / patchy loss of DNA mismatch repair protein expression by IHC

<sup>1</sup> Participant (ID\_161) developed a single endometrial cancer showing loss of MLH1/PMS2 by
 immunohistochemistry but carried two VUS; one in *MLH1* and one in *MSH6*

401 <sup>2</sup> Participant (ID 352) carried a PMS2 VUS but developed two different CRCs; one with loss of

402 MSH2/MSH6 protein expression and one with no loss of MMR protein expression (pMMR)

403

404 *3.4 Determining Somatic MMR Gene Second Hit using Tumor Sequencing Data* 

405 Following the "two-hit" model for Lynch syndrome, a somatic second hit would be expected in

406 the same gene as the gene carrying the germline variant. We aimed to identify the presence of a

407 somatic MMR mutation as the second hit in the gene carrying the germline MMR VUS. For the

408 reference group of dMMR Lynch syndrome tumors, 13 of the 16 (81.3%) harbored a detectable

409 somatic second hit in the same MMR gene harboring the germline pathogenic variant, which

It is made available under a CC-BY-NC-ND 4.0 International license .

410 included single somatic mutations (6/13, 46%) and LOH (7/13, 53.8%) (Table S1, Figure S2A). 411 Of the 18 reference pMMR non-MMR carrier tumors, only 2/18 (11.1%) harbored a somatic 412 mutation in one of the four MMR genes, both of which were LOH events (Table S1, Figure 413 S2A). The findings from these reference tumors highlights the enrichment of somatic MMR 414 mutations as second hits in Lynch syndrome related CRCs and ECs. Similarly, in the test group, 415 for 86.7% of the cases (13/15), a second hit could be identified where the MMR VUS was 416 concordant to the IHC pattern of loss. The second hit was more commonly a single somatic 417 mutation (Figure S2B). Equivalent to the reference group, for cases with no MMR loss of 418 protein expression by IHC, the second hit was exclusively of LOH mutation type (Figure S2A, 419 Figure S2B).

420 For 7/9 (77.8%) tumors from the 7 VUS reclassified by ACMG/InSiGHT framework to 421 LP, a second hit was identified (Table 3). There were two exceptions. The first was an EC diagnosed at 55-60 years from person ID\_315-2 who carried the MSH2 c.1862G>T 422 423 p.(Arg621Leu) variant but the tumor showed loss of MLH1/PMS2<sup>+</sup> expression related to tumor 424 MLH1 promoter methylation. The sister (ID 315) was also a carrier and developed an EC at 61-425 65 years, which demonstrated loss of MSH2/MSH6 expression and a somatic second hit in 426 MSH2. The second exception was an EC diagnosed at 51-55 years from ID\_156 who carried the 427 MSH6 c.3556+5 3556+9 delins variant that was MSI-H/dMMR from tumor sequencing, showed 428 solitary loss of MSH6 expression but no somatic mutation in MSH6, however, a CRC diagnosed 429 at 61-65 years in ID 156 also showed solitary loss of MSH6 expression with a second hit in 430 MSH6.

431 There were an additional 8 tumors from 7 VUS carriers that were not reclassified by 432 ACMG/InSiGHT framework, but did demonstrate a second hit (Table 3), including ID\_176 who 433 carried the MLH1 c.1594G>C p.(Gly532Arg) variant and developed MLH1/PMS2 deficient 434 CRC and EC, in the absence of MLH1 methylation, where a second hit was observed in both 435 tumors. Two VUS carriers, ID\_170 (MLH1 c.-117G>T p.?) and ID\_111 (MSH6 c.1153\_1155del 436 p.(Arg385del)), demonstrated MSI-H/dMMR by tumor sequencing and a second hit in their 437 respective CRCs, however, both CRCs were pMMR by IHC suggesting a false negative MMR 438 IHC result. An additional VUS carrier, ID 376 (MSH2 exon 1-6 duplication) whose CRC 439 showed loss of MSH2/MSH6 by IHC, MSI-H/dMMR by tumor sequencing, did not harbor a 440 second hit in the MSH2 gene (Table 3).

441 There were a further 8 VUS carriers whose tumors were all MSI-H/dMMR by tumor 442 sequencing but their pattern of MMR protein loss by IHC indicated a different MMR gene was 443 defective to the one harboring the VUS (Table 3). Tumor sequencing revealed two somatic 444 MMR mutations (also known as "double somatics"), which were likely responsible for the 445 pattern of MMR protein loss by IHC in these 8 carriers. For two of these VUS (ID 263: MSH6 446 c.\*85T>A and ID 202: MSH2 c.138C>G p.(His46Gln)) a second hit was observed, however, the 447 ACMG/InSiGHT framework reclassified these variants as benign and likely benign, respectively 448 (Table 3).

It is made available under a CC-BY-NC-ND 4.0 International license .

449 The specificity of the somatic MMR mutations to the MMR gene harboring the VUS was 450 assessed. For the reference group of dMMR Lynch syndrome tumors, a somatic second hit was 451 identified in 100% of MLH1 (n=4), in 70% of MSH2 (n=10), in 100% of MSH6 (n=1) and 100% 452 of PMS2 (n=1) germline pathogenic variant carriers but somatic MMR mutations in the other 453 MMR genes were rarely observed (Table S1). For the reference pMMR non-Lynch syndrome 454 tumors, the presence of any MMR somatic mutation was found in only 11.1% (2/18) of the cases 455 screened (Table S1). In the test group, for the MMR VUS categorized as LP by the 456 ACMG/InSiGHT framework, only 3/9 (33.3%) tumors presented with  $\geq 1$  somatic event in the 457 gene that did not harbor the germline VUS (Table 3, Figure 2). For the three cases where the 458 germline VUS was classified as LB/B, a different molecular mechanism, e.g., double somatic 459 MMR mutations (n=2) or a concomitant germline variant plus somatic second hit in the same 460 gene (n=1, ID 161), is the likely cause for the observed tumor dMMR (**Table 3**, **Figure 2**).

It is made available under a CC-BY-NC-ND 4.0 International license .

	Tu	mor	CRC_326	CRC_149	EC_315	EC_315-2	EC_008	CRC_132	CRC_156	EC_156	EC_143	EC_202	EC_161	EC_263	EC_161	EC_051	CRC_176	EC_176	CRC_170	CRC_328	EC_058	CRC_138	CRC_376	CRC_395	CRC_111	CRC_089	EC_046	CRC2_352	CRC_193	CRC_240	CRC1_352
-	Ň	VUS	<i>MLH1</i> c.1595G>A p.(Gly532Asp)	MSH2 exon 14-15 duplication p.?	MSH2 c.1862G>T p.(Arg621Leu)	MSH2 c.1862G>T p.(Arg621Leu)	MSH2 c.2005+3_2005+14del p.?	MSH2 c.2060T>C p.(Leu687Pro)	<i>MSH6</i> c.3556+5_3556+8delins p.?	MSH6 c.3556+5_3556+8delins p.?	PMS2 c.137G>T p.(Ser46lle)	MSH2 c.138C>G p.(His46Gln)	MSH6 c.4068_4071dup p.(Lys1358Aspfs*2)	<i>MSH6</i> c.*85T>A p.?	MLH1 c.539_541del p.(Val180del)	MLH1 c.71_85del p.(Val24_Pro28del)	MLH1 c.1594G>C p.(Gly532Arg)	MLH1 c.1594G>C p.(Gly532Arg)	MLH1 c117G>T p.?	MLH1 c.1153C>T p.(Arg385Cys)	MSH2 exon 1-6 duplication p.?	MSH2 c.328A>C p.(Lys110Gln)	MSH2 exon 1-6 duplication p.?	MSH2 c.668T>C p.(Leu223Pro)	MSH6 c.1153_1155del p.(Arg385del)	MSH6 c.2827G>T p.(Asp943Tyr)	MSH6 c.2950A>C p.(Asn984His)	PMS2 c.241G>A p.(Glu81Lys)	PMS2 c.2149G>A p.(Val717Met)	PMS2 c.2335G>A p.(Gly779Arg)	PMS2 c.241G>A p.(Glu81Lys)
-	MMR	IHC	MLH1+/PMS2	MSH2/MSH6	MSH2/MSH6	MLH1/PMS2+	MSH2/MSH6	MSH2/MSH6	MSH6	MSH6	PMS2	9HSM	MLH1/PMS2	MLH1+/PMS2	MLH1/PMS2	MLH1/PMS2	MLH1/PMS2	MLH1+/PMS2	Normal	MSH2/MSH6	MSH2/MSH6	MSH2/MSH6	MSH2/MSH6	MLH1/PMS2	Normal	MLH1/PMS2	PMS2	MSH2/MSH6	MLH1/PMS2	Normal	Normal
			1																												
	MLH1	germ	Y	-	÷	~	9	2		-	-	2		-	Y	Y	Y	Y	Y	Y				-	-	÷	÷	•	94	÷	*
	MLH1	germ som	Y LOH	•	-		Mut	-	•	-	- Mut	2		- LOH+ Mut	Y Mut	Y LOH+ Mut	Y LOH	Y 2x Mut	Y LOH	Υ -	•		•	- LOH+ Mut	-	- LOH+ 2xMut	-	2x Mut	2x Mut	ч -	2x Mut
	MLH1	germ som germ	Y LOH	- - Y	- - Y	ү	Mut Y	- - Y	•	•	- Mut	- - Y	•	- LOH+ Mut	Y Mut	Y LOH+ Mut	Y LOH	Y 2x Mut	Y LOH	Υ - -	- - У	- Y	- - Y	LOH+ Mut Y	-	- LOH+ 2xMut -	•	- 2x Mut -	2x Mut		- 2x Mut -
	MLH1 MSH2	germ som germ som	Y LOH -	- Y Mut	- Y Mut	• • ¥	Mut Y LOH	- Y Mut	• • •	- - -	- Mut - 2x Mut	- Y Mut	•	- LOH+ Mut -	Y Mut -	Y LOH+ Mut -	Y LOH -	Y 2x Mut -	Y LOH - L	Y - - OH+ Mut	- Y LOH	Y 2x Mut	- Y	- LOH+ Mut Y	•	- LOH+ 2xMut -	• • •	2x Mut - 2x Mut	2x Mut -	• • •	2x Mut
	MLH1 MSH2 MSH6	germ som germ som germ	ч LOH - -	- Y Mut	- Y Mut	ү	- Mut Y LOH	- Y Mut	Y	- - - Y	- Mut - 2x Mut -	- Y Mut	- - - Y	- LOH+ Mut - - Y	Y Mut -	Y LOH+ Mut - -	Y LOH -	Y 2x Mut - -	Y LOH - <sup>1</sup> -	Y - OH+ Mut	- Y LOH	- Y 2x Mut	- Y -	- LOH+ Mut Y -	- - - Y	- LOH+ 2xMut - - Y	- - - Y	2x Mut - 2x Mut -	- Mut - -	• • •	- 2x Mut -
	MLH1 MSH2 MSH6	germ som germ som germ som	ү LOH - - -	- Y Mut	- Y Mut - Mut	- Y - -	- Mut Y LOH -	- Y Mut	- - - Y Mut	- - - Y	- Mut - 2x Mut - 2x Mut	- Y Mut - 2x Mut	- - - Y	- LOH+ Mut - Y Mut	Y Mut - -	Y LOH+ Mut - - Mut	Y LOH - - Mut	Y 2x Mut - - - Mut	Y LOH - <sup>1</sup> -	Y - OH+ Mut -	- Y LOH -	Y 2x Mut 2x Mut	- Y - Mut	- LOH+ Mut Y -	- - - Y	- LOH+ 2xMut - - Y	- - - Y Mut	2x Mut - 2x Mut - Mut	- Mut - -	• • • •	2x Mut - - 2x Vut
	MLH1 MSH2 MSH6 PMS2	germ som som germ som germ	¥ LOH - - -	- Y Mut -	- Y Mut - Mut	- Y - -	- Mut V LOH -	- Y Mut -	- - - Y Mut	- - - Y	- Mut - 2x Mut - 2x Mut Y	- Y Mut - 2x Mut -	- - - Y -	LOH+ Mut - Y Mut	Y Mut - - -	Y LOH+ Mut - - Mut	Y LOH - - Mut	Y 2x Mut - - Mut	Y LOH - <sup>L</sup> - -	Y -	- Y LOH -	Y 2x Mut 2x Mut	- Y - Mut	- LOH+ Mut - -	- - - Y LOH	- LOH+ 2xMut - - Y -	- - - Y Mut	- Mut - 2x Mut - Mut Y	2x Mut - - - - Y	- - - - - - -	- Mut - - 2x Mut Y
	MLH1 MSH2 MSH6 PMS2	germ som germ germ som germ som	¥ LOH - - - - - - -	- Y Mut -	- Y Mut - Mut - Mut	· Y · ·	- Mut LOH - - Mut	- Y Mut -	- - - Y Mut -	- - - - - - - -	- Mut - 2x Mut - 2x Mut Y 2x Mut	- Y Mut - 2x Mut -	· · · · · · · · · · · · · · · · · · ·	- LOH+ Mut - Y Mut -	Y Mut - - - - -	Y LOH+ Mut - - Mut - -	Y LOH - - Mut -	Y 2x Mut - - Mut - -	Y LOH - <sup>L</sup> - - -	Y - OH+ Mut - -	- Y LOH - -	Y 2x Mut 2x Mut -	- Y - Mut -	- Mut Y - - -	- - - Y LOH	- LOH+ 2xMut - Y - Y -	- - Y Mut - 2x Mut	- Mut - 2x Mut - Mut Y -	2x Mut - - - Y	- - - - - - - - - -	- Mut - - 2x Mut Y
м	MLH1 MSH2 MSH6 PMS2 ACMG/In:	germ som germ som germ som germ som SiGHT	Y LOH - - - - - -	• • • •	- Y Mut - Mut Mut	· • • •	- Mut LOH - - Mut	- Y Mut - -	- - Y Mut	- - - - - - -	- Mut - 2x Mut - 2x Mut Y 2x Mut	- Y Mut - 2x Mut -	· · · ·	- LOH+ Mut - Y Mut -	Y Mut 	Y LOH+ Mut - Mut -	Y LOH - - Mut -	Y 2x Mut -	Y LOH - L -	Y - OH+ Mut - -	- Y LOH - -	Y 2x Mut 2x Mut	- Y - Mut Mut	- LOH+ Mut - - -	- - Y LOH	- LOH+ 2xMut - Y -	- - Y Mut - 2x Mut	- 2x Mut - 2x Mut - Mut Y	2x Mut - - - Y	- - - - - - - - - - - - - - - - - - -	- Mut - 2x - 2x Mut Y
M	MLH1 MSH2 MSH6 PMS2 ACMG/In: LH1 hyper MSI/ 2 <sup>nd</sup> soma MR crypt/	germ som germ som germ som SiGHT rmeth MMR tric hit /gland	Y LOH - - - -	Y Mut	Y Mut Mut Mut	· Y · ·	Mut Y LOH - Mut	- Y Mut - -	Y Mut	- - - - - -	- Mut - 2x Mut - 2x Mut Y 2x Mut	- Y Mut - 2x Mut -	· · · · · · · · · · · · · · · · · · ·	LOH+ Mut - Y Mut -	Y Mut - - - -	Y LOH+ Mut - Mut	Y LOH - Mut	Y 2x Mut - - - Mut	Y LOH - L	Y - OH+ - - -	Y LOH -	Y 2x Mut - 2x Mut	Y Mut Mut	LOH+ Mut Y - - -	- - Y LOH	- LOH+ 2xMut - Y - -	- - Y Mut Zx Mut	2x Mut 2x Mut - Mut Y	2x Mut - - Y	Y	- 2x Mut - - 2x Mut Y
 dM	MLH1 MSH2 MSH6 PMS2 ACMG/In: LH1 hyper MSI/ 2 <sup>nd</sup> soma MR crypt/	germ som germ som germ som som SiGHT (MMR SiGHT (MMR kich hit kich hit geland	Y LOH - - - -	Y Mut	- Y Mut Mut Mut	Y	Mut Y LOH - Mut	- Y Mut -	- - Y Mut -	Y y y y perr	Mut - 2x Mut - 2x Mut Y 2x Mut	- Y Mut - 2x Mut -	· · · · · · · · · · · · · · · · · · ·	LOH+ Mut - Y Mut -	Y Mut 	Y LOH+ - - Mut - -	Y LOH - Mut -	Y 2x Mut - - - Mut - - -	Y LOH - - - - -	Y - OH+ Mut - -	- Y LOH - -	Y Y 2x Mut - 2x Mut -	- Y - Mut - Mut	LOH+ Mut Y	- - Y LOH -	Y - - Y -	Y Y Mut 2x Mut	2x Mut - 2x Mut - Mut Y -	2x Mut - - - Y	Y	- 2x Mut - 2x Mut Y

461

462 Figure 2. Overview of the number and type of somatic events by the 25 germline DNA 463 mismatch repair variants of uncertain significance screened in this study. Red highlighted text 464 indicates duplicate entries per row. Abbreviations: VUS, variant of uncertain significance; germ, 465 germline variant; som, somatic mutation; ACMG, American College of Medical Genetics and 466 Genomics; InSiGHT, International Society for Gastrointestinal Hereditary Tumours; MMR, 467 DNA mismatch repair; dMMR, DNA mismatch repair deficient; pMMR, DNA mismatch repair 468 proficient; IHC, immunohistochemistry; MSI, microsatellite instability; MSI-H, high levels of 469 microsatellite instability; MSS, microsatellite stable; LOH, loss of heterozygosity; LP, likely 470 pathogenic; LB, likely benign; B, benign.

471 + Indicates heterogeneous / patchy loss of DNA mismatch repair protein expression by IHC

472 <sup>1</sup> Determination of the MSI/MMR status using the additive feature combination approach as

473 previously described in Walker et al., 2023

It is made available under a CC-BY-NC-ND 4.0 International license .

474

#### 475 3.5 Detection of DNA Mismatch Repair Deficient Crypts / Glands in Normal Tissue

476 To establish the protocol, screening of normal colonic mucosa for dMMR crypts was performed 477 for three pathogenic variant carriers from the reference group with available tissue. Two crypts 478 from two different carriers demonstrated a loss of expression of the MLH1 protein which was 479 concordant with the germline pathogenic variant in *MLH1* (Figure 3A, Table S1, Table 4). The 480 screening did not identify a dMMR crypt in the third reference case (Ref\_411) from 2x80µM 481 tissue screening, after which the tissue was depleted. In addition to finding a dMMR crypt in the 482 normal colonic mucosa of MLH1 pathogenic variant carrier Ref 029, a dMMR crypt was 483 identified in the normal colonic mucosa of their relative (Ref 029-2) who was also a carrier of 484 the family *MLH1* pathogenic variant (**Table 4**). No dMMR crypts were identified from 3x80µM 485 tissue screening of the normal colonic mucosa from two CRC-affected people who did not carry 486 a germline MMR pathogenic variant (Table 4).

It is made available under a CC-BY-NC-ND 4.0 International license .



#### **MMR IHC Staining**

487

Figure 3. Detection of DNA mismatch repair deficient crypts or glands in (A) the reference and
(B) the test group with three cases identified each. *Abbreviations*: MMR, DNA mismatch repair;

- 490 dMMR, DNA mismatch repair deficient; IHC, immunohistochemistry.
- 491

It is made available under a CC-BY-NC-ND 4.0 International license .

												_	
									Evaluation of Sc Addition to Cu	rreen ing Assays rrent Variant Cla Approaches	or Potential ssification		
#	Carrier Type	Carrier ID	Tissue	ІНС	<i>MLH1</i> Methylation	Gene	Va ria nt	ACMG/InSIGHT Classification	MSI-H/dMMR by Additive Feature Approach	Presence of a Somatic Second Hit	Presence of a dMMR Crypt / Gland	A mount Screened	Final Tumor Class ification
1	Reference	Ref_029	CRC	MLH1/PMS2	NT	MLH1	c.1713_1716delTGGT p.P he 571Leufs*19	Class 5: P	Yes	Ye s	Yes	2x80µM	d MMR - LS + 2nd hit  MLH1
2	Reference	Ref 029-21	CRC	MLH1/PMS2	NT	MLH1	c.1713 1716delTGGT p.Phe 571Leufs*19	Class 5: P	NA	NA	Yes	10x4µM	d MMR - LS  MLH1
3	Reference	Ref_605	CRC	MLH1/PMS2	NT	MLH1	c.1852_1854delAAG p.Lys618del	Class 5: P	Yes	Ye s	Yes	1x80µM	d MMR - LS + 2nd hit  MLH1
4	Reference	Ref_411	CRC	MS H2 / MS H6	NT	MS H2	c.1889_1892delGAAG p.G ly63 0G lufs* 4	Class 5: P	Yes	Ye s	No <sup>2</sup>	2x80µM	d MMR - LS + 2nd hit  MSH2
5	Reference	Ref 897 <sup>3</sup>	CRC	Normal	NT		Wildtype	NA	NA	NA	No	3x80µM	p MMR - non-LS
6	Reference	Ref_972 <sup>3</sup>	CRC	Normal	NT		Wildtype	NA	NA	NA	No	3x80µM	p MMR - non-LS
7	Test - Proband	ID 051	EC	MLH1/PMS2	NEGATIVE	MLH1	c.71 85del p. Val24 Pro28del	Class 3: VUS	Yes	Ye s	No	10x4µM	d MMR · VUS + 2 nd hit   MLH1
8	Test - Proband	ID_161	EC	MLH1/PMS2	NEGATIVE	MLH1	c.539_541del p. Val180del	Class 3: VUS	Yes	Ye s	No	3x80µM	d MMR - VUS + 2 nd hit  MLH1
9	Test - Proband	ID_176	CRC	MLH1/PMS2	NEGATIVE	MLH1	c.1594G>C p. Gly532Arg	Class 3: VUS	Yes	Ye s	No	3x80µM	d MMR - VUS + 2 nd hit  MLH1
10	Test - Proband	ID_326	CRC	MLH1*/PMS2	NEGATIVE	MLH1	c.1595G>A p. G ly532Asp	Class 4:LP	Yes	Ye s	No <sup>2</sup>	2x80µM	d MMR - VUS + 2 nd hit   MLH1
11	. Test - Proband	ID_058	EC	MS H2 / MS H6	NT	MS H2	Exon 1-6 d up lication	Class 3: VUS	Yes	Ye s	Yes	1x80µM	d MMR - VUS + 2 nd hit   MSH2
12	Test - Proband	ID_376	CRC	MS H2 / MS H6	NT	MS H2	Exon 1-6 d up lication	Class 3: VUS	Yes	No	No	3x80µM	d MMR - VUS  MSH2
13	Test - Proband	ID_138	CRC	MS H2 / MS H6	NT	MS H2	c.328A>C p.  Lys110G in	Class 3: VUS	Yes	Ye s	No	1x4 μM	d MMR - VUS + 2 nd hit   MSH2
14	Test - Relative	ID_315-2	EC	MLH1/PMS2*	POSITIVE	MS H2	c.1862G>T p. Arg621Leu	Class 4 : LP	No	No	Yes	1x80µM	d MMR - MLH1 methylation
15	Test - Proband	ID 132	CRC	MS H2 / MS H6	NT	MS H2	c.2060T>C p. Leu687 Pro	Class 4:LP	Yes	Ye s	No <sup>4</sup>	10x4µM	d MMR - VUS + 2 nd hit   MSH2
16	Test - Proband	ID_156	CRC	MS H6	NT	MS H6	c.3 556+5_3 556+8de lins	Class 4 : L P	Yes	Ye s	Yes	10x4µM	d MMR - VUS + 2 nd hit  MSH2
17	Test - Proband	ID_046	EC	PMS2	NEGATIVE	MS H6	c.2950A>C p. As n984His	Class 3: VUS	Yes	Ye s	No	3x80µM	d MMR - double so matic  PMS2
18	Test - Proband	ID 143	EC	P MS 2	NEGATIVE	PMS2	c.137G>T p. Ser46lle	Class 4:LP	Yes	Ye s	Failed test	3x80µM	d MMR - VUS + 2 nd hit  PMS2

493 Table 4. Overview of normal tissue screening for DNA mismatch repair deficient crypts and 494 glands in the reference and test groups. Abbreviations: ID, identification number; CRC, 495 colorectal cancer; EC, endometrial cancer; IHC, immunohistochemistry; P, pathogenic; LP, 496 likely pathogenic; VUS, variant of uncertain significance; LB, likely benign; MMR, DNA 497 mismatch repair; dMMR, DNA mismatch repair deficiency; pMMR, DNA mismatch repair 498 proficiency; MSI-H, high levels of microsatellite stability; MSS, microsatellite stable; NA, not 499 applicable; NT, not tested; LS, Lynch syndrome; MLH1me, MLH1 gene promoter 500 hypermethylation.

501 + Indicates heterogeneous / patchy loss of DNA mismatch repair protein expression by IHC

<sup>1</sup> Relative of Ref\_029 who is also carrier of the family *MLH1* pathogenic variant was identified to have a dMMR crypt in normal colonic mucosa, but their CRC did not undergo tumor sequencing

 $^{2}$  Block was depleted after screening of 2x80µM of normal tissue

<sup>3</sup> This sample did not undergo next-generation sequencing

507 <sup>4</sup> Only received slides

508

509 For 12/25 (48%) of MMR VUS carriers, normal tissue specimens (6x normal colonic and 6x 510 normal endometrial tissue) were available for dMMR crypt/gland screening. A single case 511 (ID 143) was a technical failure for PMS2 IHC staining due to poor tissue fixation of the normal 512 tissue. In 7/11 (63.6%) of the remaining cases, normal tissue blocks were available for screening 513 while for 4/11 (36.4%) of the cases, only 4µM normal tissue sections on slides were available for 514 screening. A total of three carriers (27.3%) had a dMMR crypt/gland identified out of 11 carriers 515 tested (Table 4, Figure 3B). Two of these were in normal endometrium tissue with the 516 remaining dMMR crypt identified in normal colonic mucosa. Out of four cases that were 517 reclassified as likely pathogenic based on the ACMG/InSiGHT criteria and where normal tissue 518 was available for testing, 2/4 (ID\_315: MSH2 c.1862G>T p.(Arg621Leu) and ID\_156: MSH6 519 c.3556+5 3556+8delins) had a dMMR gland and dMMR crypt identified, respectively (Table 520 4). A dMMR endometrial gland was identified in the carrier of MSH2 exon 1-6 duplication 521 (ID\_058), where the tumor also demonstrated MSI-H/dMMR by tumor sequencing, a somatic 522 second hit in MSH2 and showed loss of MSH2/MSH6 expression by IHC, however, the

It is made available under a CC-BY-NC-ND 4.0 International license .

ACMG/InSiGHT framework did not result in a reclassification of the VUS (**Table 4**). The pathogenic criterion (PVS1) from the ACMG guidelines could not be applied for a predicted loss of function as the location of the partial gene duplication was unknown, making it uncertain if nonsense mediated mRNA decay would take place [53].

527

#### 528 **4. Discussion**

529 In this study, tumor and non-malignant tissue features associated with germline pathogenic 530 MMR variant carriers were investigated to determine their utility to aid MMR variant 531 classification. Our findings from the investigation of 28 tumors from 25 VUS carriers showed 532 that tumor MSI-H/dMMR status, determined by tumor sequencing and an additive feature 533 combination approach [22], agreed with variant LP/P classification (Figure 4). We found MSI-534 H/dMMR status by tumor sequencing was 100% concordant with dMMR status by IHC in both 535 our reference group of dMMR Lynch syndrome tumors (Figure S3) and in the tumors from 7 536 VUS carriers that were reclassified to LP by the ACMG/InSiGHT framework (Table 3), while 537 the reference group of pMMR non-MMR carrier tumors were MSS/pMMR by tumor sequencing 538 (Figure S3). Furthermore, the identification of a somatic second hit was also consistent with 539 variant LP/P classification. A second hit was observed in 81.3% of the reference group of 540 dMMR Lynch syndrome tumors (Figure S3) and 77.8% of the tumors from VUS reclassified to 541 LP (**Table 3**) in contrast to only 11.1% of tumors from the reference group of pMMR non-MMR 542 carriers having a somatic MMR mutation (Figure S3). In light of these findings, a further 7 543 VUS, that could not be reclassified by the ACMG/InSiGHT framework demonstrated tumors 544 with MSI-H/dMMR and a second hit, suggesting that these 7 VUS could be upgraded to an LP 545 classification (Table 3). Screening for the presence of a dMMR crypt/gland also showed 546 potential for clinical utility for LP/P variant classification. In addition to the three known 547 pathogenic variant carriers from the reference group, three additional VUS carriers were found to 548 have a dMMR crypt/gland, where in two of these the ACMG/InSiGHT framework reclassified 549 the VUS to LP (Table 4). The remaining VUS case with a dMMR endometrial gland was 550 identified in the carrier of MSH2 exon 1-6 duplication (ID 058), and together with the tumor 551 also demonstrating MSI-H/dMMR by tumor sequencing and a somatic second hit, is supportive 552 of an LP classification for this variant (Table 4). Therefore, the application of tumor sequencing 553 for MSI/dMMR status and presence of a second hit together with testing for dMMR 554 crypts/glands is likely to improve MMR variant classification.

555 The use of tumor characteristics to support MMR variant classification continues to 556 evolve. MMR IHC and testing for somatic BRAF p.V600E mutation and/or MLH1 promoter 557 methylation are commonly used to identify or exclude CRCs and ECs for germline MMR gene 558 testing and thus these features have been incorporated into existing MMR VUS classification 559 approaches [15,16]. The investigation of somatic features derived from tumor next generation 560 sequencing to support MMR variant classification has important potential. The determination of 561 MSI/dMMR by NGS has resulted in the development of multiple accurate MSI calling tools [44-562 47], where our previous study compared these tools and other dMMR-related tumor features to

It is made available under a CC-BY-NC-ND 4.0 International license .

563 ultimately determine the combination of features (an additive feature combination approach) 564 which demonstrated the highest accuracy across tumor types [22]. In this study, we showed the 565 determination of MSI-H/dMMR by our additive feature combination approach was highly concordant with MMR IHC results, potentially identifying two VUS with false negative pMMR 566 567 IHC results (ID\_170 and ID\_111) (Table 3). Despite this promising finding, MMR IHC currently has a diagnostic advanctage over MSI-H/dMMR determination by tumor sequencing of 568 569 indicating which MMR gene is likely to be the defective gene. This was evident for 8 VUS in 570 this study where the pattern of MMR protein loss by IHC was discordant with the MMR gene 571 harboring the VUS suggesting the VUS was not likely to be pathogenic. In these 8 cases, tumor 572 sequencing revealed that two somatic MMR mutations were the cause for the pattern of MMR 573 protein loss rather than the VUS. Future incorporation of tumor next generation sequencing into 574 MMR variant classification framework should derive MSI-H/dMMR status together with 575 identification of somatic mutations across the four MMR genes to elucidate either germline or 576 biallelic somatic MMR gene inactivation as the likely cause for MSI-H/dMMR status.

577



578

It is made available under a CC-BY-NC-ND 4.0 International license .

**Figure 4.** Sunburst diagram displaying the prevalence of the three Lynch syndrome associated features in the test group. The diagram incorporates the tumor sequencing and dMMR crypt/gland screening for determining pathogenicity against the ACMG/InSiGHT framework for MMR VUS included in the test group. *Abbreviations*: MMR, DNA mismatch repair; dMMR, DNA mismatch repair deficient; pMMR, DNA mismatch repair proficient; MSI, microsatellite instability; MSI-H, high levels of microsatellite instability; MSS, microsatellite stable; VUS, variant of uncertain clinical significance; LP, likely pathogenic; LB, likely benign; B, benign.

586

587 A recent study has investigated the benefit of identifying the somatic second hit for 588 variant classification. Scott et al. (2022) showed that somatic second hit mutations in MSH2 were 589 significantly more common in tumors from MSH2 missense variant carriers that had multiplexed 590 analysis of variant effect (MAVE) data, indicating, the germline variant was functionally 591 disruptive (i.e., pathogenic variant) when compared with tumors from MSH2 missense variant 592 carriers with MAVE scores indicating the germline variant was functionally normal (i.e., benign 593 variant) [53]. This supports the observations from this study where a somatic second hit was 594 more prevalent in both known pathogenic variant carriers as well as VUS that were reclassified 595 to LP but rare in pMMR tumors.

596 A study performed by Shirts et al. (2018) demonstrated that tumor mutations in the MMR 597 genes can support both pathogenic and benign variant classification by identifying somatic driver 598 mutations compared with passenger mutations in patients with unexplained dMMR (i.e., 599 suspected Lynch syndrome or Lynch-like syndrome) [54]. Furthermore, the authors propose that 600 the cumulative evidence from independent mutations identified from sequencing unexplained 601 dMMR tumors will ultimately classify more germline MMR gene variants. Given the rarity of 602 some individual constitutional MMR gene variants, the observation of these same variants as 603 somatic mutations in multiple dMMR tumors may expedite their classification. The detection of 604 a somatic second hit, as we have shown in this study, as well as the work described by Shirts and 605 colleagues, demonstrates that the detection of somatic MMR mutations in tumors, with 606 confirmed MSI-H/dMMR status, can support MMR variant classification and warrants 607 modifications of the ACMG/InSiGHT MMR variant classification guidelines to incorporate the 608 characteristics of somatic mutations from tumor sequencing data.

609 An important finding from this study was the identification of double somatic MMR 610 mutations in an MMR gene that was not the gene harboring the VUS. Double somatic MMR 611 mutations are a recognized cause of somatic biallelic MMR gene inactivation that can lead to 612 tumor MSI-H/dMMR phenotype [23,33,55,56]. The additional information provided by the 613 pattern of MMR protein loss by IHC was supportive that the MSI-H/dMMR tumor phenotype 614 was caused by two somatic MMR mutations and not related to the VUS. Two of these VUS were 615 reclassified as LB/B, supporting the somatic mutation data but in MSI-H-dMMR tumors (Table 616 3). A caveat to these findings was the presence of two somatic *MSH2* mutations in the CRC from 617 person ID\_138 carrying the MSH2 c.328A>C p.(Lys110Gln) VUS (Table 3). One of these two somatic MSH2 mutations may represent the second hit to the germline VUS, however, the two 618

It is made available under a CC-BY-NC-ND 4.0 International license .

619 somatic *MSH2* mutations may represent somatic biallelic inactivation (**Table 3**). Of interest, the 620 MAVE data for this *MSH2* missense VUS suggests it is likely benign [57] supporting a "double 621 somatic" rather than a germline cause of MSI-H/dMMR for this tumor. Consideration of the 622 number of somatic MMR mutations identified together with MMR IHC findings will help to 623 interpret tumor sequencing data for MMR variant classification.

There were 4 tumors from 4 carriers where no loss of MMR protein expression was observed by IHC (**Table 3**). Two tumors (CRC\_240 and CRC1\_352)) were MSS/pMMR by tumor sequencing supporting IHC result. The other two tumors (CRC\_170 and CRC\_111) were MSI-H/dMMR by NGS and showed a somatic second hit in the gene with the VUS (both LOH events), which may suggest false negative MMR IHC result.

- 629 The presence of a dMMR crypt or gland is a strong predictor for a variant being pathogenic 630 given its specificity for Lynch syndrome [24–29]. In this study, a single endometrial gland 631 showed loss of MSH2 expression in the patient harboring the MSH2 exon 1-6 duplication 632 (ID\_058) which would support this variant being pathogenic (Table 4). The absence of 633 detectable dMMR crypts/glands does not conversely support a LB/B classification and could simply reflect insufficient tissue was screened. The exact prevalence of dMMR crypts/glands 634 across normal tissues still needs to be assessed in ancillary studies, however, Kloor et al. (2012) 635 have indicated the detection of dMMR crypts in 1cm<sup>2</sup> of colonic mucosa in Lynch syndrome 636 637 patients [24]. The feasibility in terms of the amount of biopsy needed to get at least  $1 \text{ cm}^2$  and 638 cost-effectiveness of screening for dMMR crypts/glands in clinical setting needs to be 639 determined but may offer an alternate approach to reclassify an MMR variant particularly when 640 evidence from the existing ACMG/InSiGHT framework is insufficient.
- 641 A strength of the study was the comparison of data from the existing gold standard MMR variant classification framework to the application of novel features, particularly those derived 642 643 from NGS which is increasing in clinical diagnostics. The detection of MSI-H/dMMR and a 644 second hit from tumor sequencing is unlikely to be influenced by the type of variant. Further 645 studies are needed to determine if the detection of dMMR crypts/glands is likely to be influenced 646 by variant type. Furthermore, the implementation of screening for dMMR crypts or glands would 647 be based on established MMR protein antibodies and immunohistochemical protocols and, 648 therefore, potentially more applicable to a broader spectrum of laboratories once the tissue is 649 available. A further demonstrated strength by this study was the ability to detect dMMR 650 crypts/glands on FFPE archival tissue that was up to 20 years old (e.g., reference group tissue) 651 with only a single case (ID\_143) failing testing.
- This study has several limitations. An important caveat for interpreting the presence of a dMMR crypt/gland for VUS classification is the concept that another undetected pathogenic variant underlies the dMMR crypt/gland rather than the VUS. Therefore, interpretation of the preence of a dMMR crypt/gland should be considered alone but together with additional information used to classify MMR variants. Another limitation of the study was access to normal tissue as we were only able to acquire normal tissue specimen for half of the cases (48%, 12/25). Broader recognition that screening for dMMR crypts/glands has utility for variant classification

It is made available under a CC-BY-NC-ND 4.0 International license .

659 may encourage better collection and access to normal tissue. A single Lynch syndrome tumor 660 phenocopy was identified in the case of ID 315-2, where the tumor was positive for MLH1 661 methylation despite the person carrying the MSH2 LP variant. Although phenocopies in Lynch 662 syndrome are rare, the interpretation of tumor data for MMR variant classification needs detailed 663 examination. Lastly, it is possible that somatic second hits were missed in some of the tumors. 664 This was evident for the Lynch syndrome reference tumors where a second hit was identified in 665 only 81.3% of sequenced tumors. Challenges in identifying more complex/cryptic variants from 666 capture-based sequencing data or the possibility the second hit is an intronic variant not targeted 667 by the capture may explain the missing second hits. These challenges may underlie second hit 668 detection in the VUS cases tested in this study where, for example, the EC from person ID 156 669 who carried the MSH6 c.3556+5 3556+9 delins variant and CRC from person ID 376 who 670 carried the MSH2 exon 1-6 duplication did not identify a second hit despite the other cumulative 671 evidence suggesting these variants are likely pathogenic. Lastly, complementary data could be 672 gained from functional assays such as RT-PCR or minigene constructs to provide further 673 functional evidence to support variant classification.

674

#### 675 **5. Conclusions**

676 This study evaluated novel approaches to classify MMR variants, providing support for their 677 potential incorporation into current variant classification guidelines as additional independent 678 lines of evidence to aid MMR variant classification. Currently, somatic MMR mutation data is 679 not used in MMR gene variant classification frameworks, but this study and other studies 680 provide support for information gained from sequencing of dMMR tumors. Although the 681 presence of a somatic second hit was concordant with LP/P variant classification, the knowledge 682 that the presence of two somatic MMR gene mutations (double somatics) can also result in MSI-683 H/dMMR tumor phenotype needs to be acknowledged when interpreting tumor sequencing 684 findings for variant classification. Furthermore, somatic MMR mutation data from tumor 685 sequencing needs to be considered in conjunction with confirmation the tumor is MSI-H/dMMR. 686 The presence of a dMMR crypt/gland in normal colonic or endometrial tissue represents a novel 687 approach to guide LP/P MMR variant classification. The identification of germline MMR VUS 688 prior to surgery may facilitate preservation of more normal tissue for testing but the application 689 of dMMR crypt/gland detection using normal colonic biopsies from colonoscopy in unaffected 690 VUS carriers needs further investigation. Our findings have shown the potential utility of tumor 691 sequencing to determine both MSI/MMR status and presence of single point mutation/LOH as a 692 somatic second hit, and with assessment of normal tissue for the presence of dMMR 693 crypts/glands for improving MMR variant classification and warrants consideration for inclusion 694 in the ACMG/InSiGHT framework.

695

696 Supplementary Materials: Figure S1: Bar plot presenting the feature count for targeted panel
 697 sequenced (A) reference and (B) test groups to determine the DNA mismatch repair status in
 698 next-generation sequencing screened tumors after applying the additive feature combination

It is made available under a CC-BY-NC-ND 4.0 International license .

approach; Figure S2: Pie charts presenting the proportions of the presence of a somatic second
hit and by which mutation type for (A) the reference and (B) the test groups; Figure S3:
Flowchart displaying the prevalence of the three Lynch syndrome associated features in the
reference group; Table S1: Overview of tumors included in the reference group.

703

704 Author Contributions: RW, IMW and DDB contributed to the conception and design of the 705 study. IMW, DDB, MAJ, FAM, SJ, RA, JB, MB, AC, EE, MG, AG, MTH, EI, JK, JM, HM, 706 CN, NP, AR, AS and RS contributed to the recruitment of study participants. RW, MC, JEJ, JC 707 and SGP contributed to sample preparation and quality control. RW, MC, JEJ, KM, PG and 708 DDB contributed to the data analysis. RW, MC, JEJ, KM, PG and DDB contributed to the 709 interpretation of findings. RW and JMC generated the pedigrees using Python. CR, RKP and MC 710 reviewed IHC findings. RW and DDB drafted and substantively revised the manuscript. RW, 711 IMW and DDB contributed to the overall supervision of the project. All authors have read and 712 agreed to the published version of the manuscript.

713

714 Funding: This project was funded by a National Health and Medical Research Council of 715 Australia (NHMRC) project grant GNT1125269 (PI- Daniel Buchanan). DDB is supported by an 716 NHMRC Investigator grant (GNT1194896) and University of Melbourne Dame Kate Campbell 717 Fellowship. RW is supported by the Margaret and Irene Stewardson Fund Scholarship and by the 718 Melbourne Research Scholarship. PG is supported by the University of Melbourne Research 719 Scholarship. MAJ is supported by an NHMRC Investigator grant (GNT1195099). The Colon Cancer Family Registry (CCFR, www.coloncfr.org) is supported in part by funding from the 720 721 National Cancer Institute (NCI), National Institutes of Health (NIH) (award U01 CA167551). 722 Support for case ascertainment was provided in part from the Surveillance, Epidemiology, and 723 End Results (SEER) Program and the following U.S. state cancer registries: AZ, CO, MN, NC, 724 NH; and by the Victoria Cancer Registry (Australia) and Ontario Cancer Registry (Canada).

725

**Institutional Review Board Statement:** The study was conducted in accordance with the
Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee)
of The University of Melbourne (protocol code HREC#1750748, approval date: 30<sup>th</sup> of July
2018).

730

731 Informed Consent Statement: Informed consent was obtained from all subjects involved in the732 study.

733

Data Availability Statement: The original contributions presented in the study are included in
 the article/supplementary files, further inquiries can be directed to the corresponding author.

736

Acknowledgments: The authors thank members of the Colorectal Oncogenomics Group and
 members from the Genomic Medicine and Family Cancer Clinic for their support of this

It is made available under a CC-BY-NC-ND 4.0 International license .

739 manuscript. We thank the participants and staff from the ANGELS study and from the 740 Australasian site of the Colon Cancer Family Registry (ACCFR), in particular Maggie 741 Angelakos, Samantha Fox, and Allyson Templeton for their support of this manuscript. The 742 authors thank the Australian Genome Research Facility for their collaboration on this project. 743 The CCFR graciously thanks the generous contributions of their 42,505 study participants, 744 dedication of study staff, and the financial support from the U.S. National Cancer Institute, 745 without which this important registry would not exist. The content of this manuscript does not 746 necessarily reflect the views or policies of the NIH or any of the collaborating centers in the 747 CCFR, nor does mention of trade names, commercial products, or organizations imply 748 endorsement by the US Government, any cancer registry, or the CCFR.

749

750 Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the 751 design of the study; in the collection, analyses, or interpretation of data; in the writing of the

- 752 manuscript; or in the decision to publish the results.
- 753

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 754 **References**

- 755 Win, A.K.: Jenkins, M.A.: Dowty, J.G.: Antoniou, A.C.: Lee, A.: Giles, G.G.: Buchanan, 1. 756 D.D.; Clendenning, M.; Rosty, C.; Ahnen, D.J.; et al. Prevalence and Penetrance of Major Genes 757 and Polygenes for Colorectal Cancer. Cancer Epidemiol Biomarkers Prev 2017, 26, 404-412,
- 758 doi:10.1158/1055-9965.EPI-16-0693.
- 759 Buchanan, D.D.; Clendenning, M.; Rosty, C.; Eriksen, S.V.; Walsh, M.D.; Walters, R.J.; 2.
- 760 Thibodeau, S.N.; Stewart, J.; Preston, S.; Win, A.K.; et al. Tumour Testing to Identify Lynch
- 761 Syndrome in Two Australian Colorectal Cancer Cohorts. J Gastroenterol Hepatol 2017, 32,
- 762 427-438, doi:10.1111/jgh.13468.
- 763 3. Buchanan, D.D.; Rosty, C.; Clendenning, M.; Spurdle, A.B.; Win, A.K. Clinical
- 764 Problems of Colorectal Cancer and Endometrial Cancer Cases with Unknown Cause of Tumor
- 765 Mismatch Repair Deficiency (Suspected Lynch Syndrome). Appl Clin Genet 2014, 7, 183–193, 766 doi:10.2147/TACG.S48625.
- 767 4. Moreira, L.; Balaguer, F.; Lindor, N.; de la Chapelle, A.; Hampel, H.; Aaltonen, L.A.;
- 768 Hopper, J.L.; Le Marchand, L.; Gallinger, S.; Newcomb, P.A.; et al. Identification of Lynch
- 769 Syndrome among Patients with Colorectal Cancer. JAMA 2012, 308, 1555–1565,
- 770 doi:10.1001/jama.2012.13088.
- 771 5. Seppälä, T.T.; Burkhart, R.A.; Katona, B.W. Hereditary Colorectal, Gastric, and
- 772 Pancreatic Cancer: Comprehensive Review. BJS Open 2023, 7, zrad023,
- 773 doi:10.1093/bjsopen/zrad023.
- 774 Lynch, H.T.; Lynch, P.M.; Lanspa, S.J.; Snyder, C.L.; Lynch, J.F.; Boland, C.R. Review 6. 775 of the Lynch Syndrome: History, Molecular Genetics, Screening, Differential Diagnosis, and
- 776
- Medicolegal Ramifications. Clin Genet 2009, 76, 1–18, doi:10.1111/j.1399-0004.2009.01230.x. 777
- Ligtenberg, M.J.; Kuiper, R.P.; Chan, T.L.; Goossens, M.; Hebeda, K.M.; Voorendt, M.; 7.
- 778 Lee, T.Y.; Bodmer, D.; Hoenselaar, E.; Hendriks-Cornelissen, S.J.; et al. Heritable Somatic
- 779 Methylation and Inactivation of MSH2 in Families with Lynch Syndrome Due to Deletion of the 780 3' Exons of TACSTD1. Nat Genet 2009, 41, 112–117, doi:10.1038/ng.283.
- 781 Moller, P. The Prospective Lynch Syndrome Database Reports Enable Evidence-Based 8.
- 782 Personal Precision Health Care. Hered Cancer Clin Pract 2020, doi:10.1186/s13053-020-0138-783 0.
- 784 9. Dowty, J.G.; Win, A.K.; Buchanan, D.D.; Lindor, N.M.; Macrae, F.A.; Clendenning, M.;
- 785 Antill, Y.C.; Thibodeau, S.N.; Casey, G.; Gallinger, S.; et al. Cancer Risks for MLH1 and MSH2
- 786 Mutation Carriers. Hum Mutat 2013, 34, 490-497, doi:10.1002/humu.22262.
- 787 Møller, P.; Seppälä, T.T.; Bernstein, I.; Holinski-Feder, E.; Sala, P.; Gareth Evans, D.; 10.
- 788 Lindblom, A.; Macrae, F.; Blanco, I.; Sijmons, R.H.; et al. Cancer Risk and Survival in
- 789 Path MMR Carriers by Gene and Gender up to 75 Years of Age: A Report from the Prospective
- 790 Lynch Syndrome Database. Gut 2018, 67, 1306–1316, doi:10.1136/gutinl-2017-314057.
- 791 Vasen, H.F.A.; Möslein, G.; Alonso, A.; Bernstein, I.; Bertario, L.; Blanco, I.; Burn, J.; 11.
- 792 Capella, G.; Engel, C.; Frayling, I.; et al. Guidelines for the Clinical Management of Lynch

- 793 Syndrome (Hereditary Non Dolyposis Cancer). J Med Genet 2007, 44, 353–362,
- 794 doi:10.1136/jmg.2007.048991.
- 795 12. Rubenstein, J.H.; Enns, R.; Heidelbaugh, J.; Barkun, A.; Adams, M.A.; Dorn, S.D.;
- 796 Dudley-Brown, S.L.; Flamm, S.L.; Gellad, Z.F.; Gruss, C.B.; et al. American
- 797 Gastroenterological Association Institute Guideline on the Diagnosis and Management of Lynch
- 798 Syndrome. *Gastroenterology* **2015**, *149*, 777–782, doi:10.1053/j.gastro.2015.07.036.
- 13. Adam, F.; Fluri, M.; Scherz, A.; Rabaglio, M. Occurrence of Variants of Unknown
- 800 Clinical Significance in Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome
- 801 and Lynch Syndrome: A Literature Review and Analytical Observational Retrospective Cohort
- 802 Study. *BMC Med Genomics* **2023**, *16*, 7, doi:10.1186/s12920-023-01437-7.
- 803 14. Vasen, H.F.A.; Blanco, I.; Aktan-Collan, K.; Gopie, J.P.; Alonso, A.; Aretz, S.;
- 804 Bernstein, I.; Bertario, L.; Burn, J.; Capella, G.; et al. Revised Guidelines for the Clinical
- 805 Management of Lynch Syndrome (HNPCC): Recommendations by a Group of European
- 806 Experts. *Gut* **2013**, *62*, 812–823, doi:10.1136/gutjnl-2012-304356.
- 807 15. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.;
- Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and Guidelines for the Interpretation of
- 809 Sequence Variants: A Joint Consensus Recommendation of the American College of Medical
- 810 Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015, *17*, 405–
  424, doi:10.1038/gim.2015.30.
- 16. Thompson, B.A.; Goldgar, D.E.; Paterson, C.; Clendenning, M.; Walters, R.; Arnold, S.;
- 813 Parsons, M.T.; Walsh, M.D.; Gallinger, S.; Haile, R.W.; et al. A Multifactorial Likelihood Model
- 814 for MMR Gene Variant Classification Incorporating Probabilities Based on Sequence
- 815 Bioinformatics and Tumor Characteristics: A Report from the Colon Cancer Family Registry.
- 816 *Hum Mutat* **2013**, *34*, 200–209, doi:10.1002/humu.22213.
- 817 17. Baretti, M.; Le, D.T. DNA Mismatch Repair in Cancer. Pharmacol Ther 2018, 189, 45–
- 818 62, doi:10.1016/j.pharmthera.2018.04.004.
- 819 18. Chen, M.-L.; Chen, J.-Y.; Hu, J.; Chen, Q.; Yu, L.-X.; Liu, B.-R.; Qian, X.-P.; Yang, M.
- 820 Comparison of Microsatellite Status Detection Methods in Colorectal Carcinoma. *Int J Clin Exp*821 *Pathol* 2018, *11*, 1431–1438.
- 822 19. Wang, Y.; Shi, C.; Eisenberg, R.; Vnencak-Jones, C.L. Differences in Microsatellite
- 823 Instability Profiles between Endometrioid and Colorectal Cancers. *J Mol Diagn* **2017**, *19*, 57–64, doi:10.1016/j.jmoldx.2016.07.008
- 824 doi:10.1016/j.jmoldx.2016.07.008.
- 825 20. Knudson, A.G. Mutation and Cancer: Statistical Study of Retinoblastoma. *Proc Natl*
- 826 *Acad Sci U S A* **1971**, *68*, 820–823.
- 827 21. Hill, B.L.; Graf, R.P.; Shah, K.; Danziger, N.; Lin, D.I.; Quintanilha, J.; Li, G.;
- 828 Haberberger, J.; Ross, J.S.; Santin, A.D.; et al. Mismatch Repair Deficiency, next-Generation
- 829 Sequencing-Based Microsatellite Instability, and Tumor Mutational Burden as Predictive
- 830 Biomarkers for Immune Checkpoint Inhibitor Effectiveness in Frontline Treatment of Advanced
- 831 Stage Endometrial Cancer. Int J Gynecol Cancer 2023, ijgc-2022-004026, doi:10.1136/ijgc-
- 832 2022-004026.

It is made available under a CC-BY-NC-ND 4.0 International license .

Walker, R.; Georgeson, P.; Mahmood, K.; Joo, J.E.; Makalic, E.; Clendenning, M.; 833 22. 834 Como, J.: Preston, S.: Joseland, S.: Pope, B.J.: et al. Evaluating Multiple Next-Generation 835 Sequencing–Derived Tumor Features to Accurately Predict DNA Mismatch Repair Status. The 836 Journal of Molecular Diagnostics 2023, 25, 94–109, doi:10.1016/j.jmoldx.2022.10.003. 837 23. Haraldsdottir, S.; Hampel, H.; Tomsic, J.; Frankel, W.L.; Pearlman, R.; de la Chapelle, 838 A.; Pritchard, C.C. Colon and Endometrial Cancers with Mismatch Repair Deficiency Can Arise 839 from Somatic, Rather than Germline, Mutations. Gastroenterology 2014, 147, 1308-1316.e1, 840 doi:10.1053/j.gastro.2014.08.041. 841 Kloor, M.; Huth, C.; Voigt, A.Y.; Benner, A.; Schirmacher, P.; von Knebel Doeberitz, 24. 842 M.; Bläker, H. Prevalence of Mismatch Repair-Deficient Crypt Foci in Lynch Syndrome: A 843 Pathological Study. Lancet Oncol 2012, 13, 598-606, doi:10.1016/S1470-2045(12)70109-2. 844 Shia, J.; Stadler, Z.K.; Weiser, M.R.; Vakiani, E.; Mendelsohn, R.; Markowitz, A.J.; 25. 845 Shike, M.; Boland, C.R.; Klimstra, D.S. Mismatch Repair Deficient-Crypts in Non-Neoplastic 846 Colonic Mucosa in Lynch Syndrome: Insights from an Illustrative Case. Familial Cancer 2015, 847 14, 61-68, doi:10.1007/s10689-014-9751-2. 848 26. Staffa, L.; Echterdiek, F.; Nelius, N.; Benner, A.; Werft, W.; Lahrmann, B.; Grabe, N.; 849 Schneider, M.; Tariverdian, M.; von Knebel Doeberitz, M.; et al. Mismatch Repair-Deficient 850 Crypt Foci in Lynch Syndrome--Molecular Alterations and Association with Clinical 851 Parameters. PLoS One 2015, 10, e0121980, doi:10.1371/journal.pone.0121980. 852 27. Pai, R.K.; Dudley, B.; Karloski, E.; Brand, R.E.; O'Callaghan, N.; Rosty, C.; Buchanan, 853 D.D.; Jenkins, M.A.; Thibodeau, S.N.; French, A.J.; et al. DNA Mismatch Repair Protein 854 Deficient Non-Neoplastic Colonic Crypts: A Novel Indicator of Lynch Syndrome. Mod Pathol 855 **2018**, *31*, 1608–1618, doi:10.1038/s41379-018-0079-6. 856 Lof, P.; Lok, C. a. R.; Snaebjornsson, P.; McCluggage, W.G.; Dorpe, J.V.; Tummers, P.; 28. 857 Vijver, K.V. de EP563 Mismatch Repair Deficiency Glands in Normal Endometrial Tissue as a 858 Predictor of Endometrial Carcinoma in Patients with Lynch Syndrome. International Journal of 859 *Gynecologic Cancer* **2019**, *29*, doi:10.1136/ijgc-2019-ESGO.620. 860 Wong, S.: Hui, P.: Buza, N. Frequent Loss of Mutation-Specific Mismatch Repair Protein 29. 861 Expression in Nonneoplastic Endometrium of Lynch Syndrome Patients. Modern Pathology 2020, 33, 1172-1181, doi:10.1038/s41379-020-0455-x. 862 863 30. Yurgelun, M.B.; Hampel, H. Recent Advances in Lynch Syndrome: Diagnosis, 864 Treatment, and Cancer Prevention. American Society of Clinical Oncology Educational Book 865 **2018**, 101–109, doi:10.1200/EDBK\_208341. 866 Christakis, A.G.; Papke, D.J.; Nowak, J.A.; Yurgelun, M.B.; Agoston, A.T.; Lindeman, 31. 867 N.I.; MacConaill, L.E.; Sholl, L.M.; Dong, F. Targeted Cancer Next-Generation Sequencing as a 868 Primary Screening Tool for Microsatellite Instability and Lynch Syndrome in Upper 869 Gastrointestinal Tract Cancers. Cancer Epidemiology, Biomarkers & Prevention 2019, 28, 1246-870 1251, doi:10.1158/1055-9965.EPI-18-1250. 871 32. Georgeson, P.; Pope, B.J.; Rosty, C.; Clendenning, M.; Mahmood, K.; Joo, J.E.; Walker, 872 R.; Hutchinson, R.A.; Preston, S.; Como, J.; et al. Evaluating the Utility of Tumour Mutational

- 873 Signatures for Identifying Hereditary Colorectal Cancer and Polyposis Syndrome Carriers. *Gut*874 **2021**, 70, 2138–2149, doi:10.1136/gutjnl-2019-320462.
- 875 33. Walker, R.; Mahmood, K.; Joo, J.E.; Clendenning, M.; Georgeson, P.; Como, J.;
- Joseland, S.; Preston, S.G.; Antill, Y.; Austin, R.; et al. A Tumor Focused Approach to
- 877 Resolving the Etiology of DNA Mismatch Repair Deficient Tumors Classified as Suspected
- 878 Lynch Syndrome. Journal of Translational Medicine 2023, 21, 282, doi:10.1186/s12967-023-
- 879 04143-1.
- 880 34. Buchanan, D.D.; Tan, Y.Y.; Walsh, M.D.; Clendenning, M.; Metcalf, A.M.; Ferguson,
- K.; Arnold, S.T.; Thompson, B.A.; Lose, F.A.; Parsons, M.T.; et al. Tumor Mismatch Repair
- 882 Immunohistochemistry and DNA MLH1 Methylation Testing of Patients with Endometrial
- 883 Cancer Diagnosed at Age Younger than 60 Years Optimizes Triage for Population-Level
- 884 Germline Mismatch Repair Gene Mutation Testing. J Clin Oncol 2014, 32, 90–100,
- 885 doi:10.1200/JCO.2013.51.2129.
- 35. Jenkins, M.A.; Win, A.K.; Templeton, A.S.; Angelakos, M.S.; Buchanan, D.D.;
- 887 Cotterchio, M.; Figueiredo, J.C.; Thibodeau, S.N.; Baron, J.A.; Potter, J.D.; et al. Cohort Profile:
- The Colon Cancer Family Registry Cohort (CCFRC). *Int J Epidemiol* 2018, 47, 387–388i,
  doi:10.1093/ije/dyy006.
- 890 36. Newcomb, P.A.; Baron, J.; Cotterchio, M.; Gallinger, S.; Grove, J.; Haile, R.; Hall, D.;
- 891 Hopper, J.L.; Jass, J.; Le Marchand, L.; et al. Colon Cancer Family Registry: An International
- 892 Resource for Studies of the Genetic Epidemiology of Colon Cancer. *Cancer Epidemiol*
- 893 Biomarkers Prev 2007, 16, 2331–2343, doi:10.1158/1055-9965.EPI-07-0648.
- 894 37. Wojdacz, T.K.; Dobrovic, A. Methylation-Sensitive High Resolution Melting (MS-
- HRM): A New Approach for Sensitive and High-Throughput Assessment of Methylation.
- 896 *Nucleic acids research* **2007**, *35*, doi:10.1093/nar/gkm013.
- 897 38. Bolger, A.M.; Lohse, M.; Usadel, B. Trimmomatic: A Flexible Trimmer for Illumina
- 898 Sequence Data. *Bioinformatics* **2014**, *30*, 2114–2120, doi:10.1093/bioinformatics/btu170.
- 899 39. Benjamin, D.; Sato, T.; Cibulskis, K.; Getz, G.; Stewart, C.; Lichtenstein, L. Calling
  900 Somatic SNVs and Indels with Mutect 2019.
- 901 40. Saunders, C.T.; Wong, W.S.W.; Swamy, S.; Becq, J.; Murray, L.J.; Cheetham, R.K.
- 902 Strelka: Accurate Somatic Small-Variant Calling from Sequenced Tumor–Normal Sample Pairs.
- 903 *Bioinformatics* **2012**, *28*, 1811–1817, doi:10.1093/bioinformatics/bts271.
- 41. Tate, J.G.; Bamford, S.; Jubb, H.C.; Sondka, Z.; Beare, D.M.; Bindal, N.; Boutselakis,
- H.; Cole, C.G.; Creatore, C.; Dawson, E.; et al. COSMIC: The Catalogue Of Somatic Mutations
  In Cancer. *Nucleic Acids Res* 2019, *47*, D941–D947, doi:10.1093/nar/gky1015.
- 907 42. Kopanos, C.; Tsiolkas, V.; Kouris, A.; Chapple, C.E.; Albarca Aguilera, M.; Meyer, R.;
- 908 Massouras, A. VarSome: The Human Genomic Variant Search Engine. *Bioinformatics* **2019**, *35*,
- 909 1978–1980, doi:10.1093/bioinformatics/bty897.
- 910 43. Robinson, J.T.; Thorvaldsdóttir, H.; Winckler, W.; Guttman, M.; Lander, E.S.; Getz, G.;
- 911 Mesirov, J.P. Integrative Genomics Viewer. *Nat Biotechnol* **2011**, *29*, 24–26,
- 912 doi:10.1038/nbt.1754.

- 913 44. Maruvka, Y.E.; Mouw, K.W.; Karlic, R.; Parasuraman, P.; Kamburov, A.; Polak, P.;
- 914 Haradhvala, N.J.; Hess, J.M.; Rheinbay, E.; Brody, Y.; et al. Analysis of Somatic Microsatellite
- 915 Indels Identifies Driver Events in Human Tumors. Nat Biotechnol 2017, 35, 951–959,
- 916 doi:10.1038/nbt.3966.
- 917 45. Kautto, E.A.; Bonneville, R.; Miya, J.; Yu, L.; Krook, M.A.; Reeser, J.W.;
- 918 Roychowdhury, S. Performance Evaluation for Rapid Detection of Pan-Cancer Microsatellite
- 919 Instability with MANTIS. Oncotarget 2017, 8, 7452–7463, doi:10.18632/oncotarget.13918.
- 920 Ni Huang, M.; McPherson, J.R.; Cutcutache, I.; Teh, B.T.; Tan, P.; Rozen, S.G. MSIseq: 46.
- 921 Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations. Sci Rep 922 **2015**, *5*, 13321, doi:10.1038/srep13321.
- 923 Niu, B.; Ye, K.; Zhang, O.; Lu, C.; Xie, M.; McLellan, M.D.; Wendl, M.C.; Ding, L. 47.
- 924 MSIsensor: Microsatellite Instability Detection Using Paired Tumor-Normal Sequence Data.
- 925 Bioinformatics 2014, 30, 1015–1016, doi:10.1093/bioinformatics/btt755.
- 926 48. Stone, E.A.; Sidow, A. Physicochemical Constraint Violation by Missense Substitutions
- 927 Mediates Impairment of Protein Function and Disease Severity. Genome Res 2005, 15, 978–986, 928 doi:10.1101/gr.3804205.
- 929 49. Adzhubei, I.A.; Schmidt, S.; Peshkin, L.; Ramensky, V.E.; Gerasimova, A.; Bork, P.;
- 930 Kondrashov, A.S.; Sunvaev, S.R. A Method and Server for Predicting Damaging Missense 931
- Mutations. Nat Methods 2010, 7, 248–249, doi:10.1038/nmeth0410-248.
- 932 Li, S.; Qian, D.; Thompson, B.A.; Gutierrez, S.; Wu, S.; Pesaran, T.; LaDuca, H.; Lu, H.-50.
- 933 M.; Chao, E.C.; Black, M.H. Tumour Characteristics Provide Evidence for Germline Mismatch
- 934 Repair Missense Variant Pathogenicity. Journal of Medical Genetics 2020, 57, 62-69,
- 935 doi:10.1136/jmedgenet-2019-106096.
- 936 Thompson, B.A.; Spurdle, A.B.; Plazzer, J.-P.; Greenblatt, M.S.; Akagi, K.; Al-Mulla, F.; 51.
- 937 Bapat, B.; Bernstein, I.; Capellá, G.; den Dunnen, J.T.; et al. Application of a 5-Tiered Scheme
- 938 for Standardized Classification of 2,360 Unique Mismatch Repair Gene Variants in the InSiGHT
- 939 Locus-Specific Database. Nat Genet 2014, 46, 107-115, doi:10.1038/ng.2854.
- 940 52. Jaganathan, K.; Panagiotopoulou, S.K.; McRae, J.F.; Darbandi, S.F.; Knowles, D.; Li,
- 941 Y.I.; Kosmicki, J.A.; Arbelaez, J.; Cui, W.; Schwartz, G.B.; et al. Predicting Splicing from
- 942 Primary Sequence with Deep Learning. Cell 2019, 176, 535-548.e24,
- 943 doi:10.1016/j.cell.2018.12.015.
- 944 Scott, A.; Hernandez, F.; Chamberlin, A.; Smith, C.; Karam, R.; Kitzman, J.O. 53.
- 945 Saturation-Scale Functional Evidence Supports Clinical Variant Interpretation in Lynch
- 946 Syndrome. Genome Biology 2022, 23, 266, doi:10.1186/s13059-022-02839-z.
- 947 54. Shirts, B.H.; Konnick, E.Q.; Upham, S.; Walsh, T.; Ranola, J.M.O.; Jacobson, A.L.;
- 948 King, M.-C.; Pearlman, R.; Hampel, H.; Pritchard, C.C. Using Somatic Mutations from Tumors
- 949 to Classify Variants in Mismatch Repair Genes. Am J Hum Genet 2018, 103, 19-29,
- 950 doi:10.1016/j.ajhg.2018.05.001.
- 951 55. Mensenkamp, A.R.; Vogelaar, I.P.; van Zelst-Stams, W.A.G.; Goossens, M.; Ouchene,
- 952 H.; Hendriks-Cornelissen, S.J.B.; Kwint, M.P.; Hoogerbrugge, N.; Nagtegaal, I.D.; Ligtenberg,

- 953 M.J.L. Somatic Mutations in MLH1 and MSH2 Are a Frequent Cause of Mismatch-Repair
- 954 Deficiency in Lynch Syndrome-like Tumors. *Gastroenterology* **2014**, *146*, 643-646.e8,
- 955 doi:10.1053/j.gastro.2013.12.002.
- 956 56. Elze, L.; Mensenkamp, A.R.; Nagtegaal, I.D.; van Zelst-Stams, W.A.G.; Dutch LS-Like
- 957 Study Group; de Voer, R.M.; Ligtenberg, M.J.L. Somatic Nonepigenetic Mismatch Repair Gene
- 958 Aberrations Underly Most Mismatch Repair-Deficient Lynch-Like Tumors. *Gastroenterology*
- 959 **2021**, *160*, 1414-1416.e3, doi:10.1053/j.gastro.2020.11.042.
- 960 57. Jia, X.; Burugula, B.B.; Chen, V.; Lemons, R.M.; Jayakody, S.; Maksutova, M.;
- 961 Kitzman, J.O. Massively Parallel Functional Testing of MSH2 Missense Variants Conferring
- 962 Lynch Syndrome Risk. *Am J Hum Genet* **2021**, *108*, 163–175, doi:10.1016/j.ajhg.2020.12.003.
- 963